

---

## CURRICULUM VITAE

**CRAIG R. LEE, PHARM.D., PH.D., FCCP, FAHA**

---

### PERSONAL INFORMATION

**Office Address:** Campus Box 7569, 3318 Kerr Hall  
Division of Pharmacotherapy and Experimental Therapeutics  
UNC Eshelman School of Pharmacy  
University of North Carolina at Chapel Hill  
Chapel Hill, NC 27599-7569  
Office: (919) 843-7673  
Lab: (919) 966-9105  
Fax: (919) 962-0644  
Email: craig\_lee@unc.edu

### EDUCATION AND TRAINING

**Doctor of Pharmacy with Highest Distinction and Honors** 1994 - 2000  
School of Pharmacy  
University of North Carolina at Chapel Hill

**Fellowship, Clinical Research / Drug Development** 2000 - 2002  
Division of Pharmacotherapy  
School of Pharmacy  
University of North Carolina at Chapel Hill

Project: *Characterization of CYP2C9 Genotype:Phenotype Relationships in Healthy Volunteers*

Co-major advisors: John A. Pieper, Pharm.D. and J. Herbert Patterson, Pharm.D.

Clinical Development and Medical Affairs (Cardiovascular & Genitourinary)  
GlaxoSmithKline, Inc.  
Research Triangle Park, NC

Major advisor: Amy M. Meadowcroft, Pharm.D.

**Doctor of Philosophy in Pharmaceutical Sciences** 2002 - 2006  
Division of Pharmacotherapy and Experimental Therapeutics  
School of Pharmacy  
University of North Carolina at Chapel Hill

Dissertation: *Cytochrome P450 Derived Eicosanoids, Endothelial Function and Cardiovascular Disease*

Major advisor: Darryl C. Zeldin, M.D. (NIH/NIEHS)

Committee Chair: J. Herbert Patterson, Pharm.D. (UNC)

## **PROFESSIONAL EXPERIENCE**

### **Registered Pharmacist**

North Carolina, License No. 15450 2000 - present

### **Guest Researcher**

Laboratory of Respiratory Biology, Division of Intramural Research  
National Institute of Environmental Health Sciences, NIH 2002 - 2006

### **Assistant Professor of Pharmacy**

Division of Pharmacotherapy and Experimental Therapeutics  
UNC Eshelman School of Pharmacy 2006 - 2012

### **Associate Professor of Pharmacy (with Tenure)**

Division of Pharmacotherapy and Experimental Therapeutics  
UNC Eshelman School of Pharmacy 2012 - present

### **Associate Professor of Medicine (Adjunct)**

Division of Cardiology, Department of Medicine  
UNC School of Medicine 2020 - present

## **Leadership Positions**

### **Division Director of Graduate Admissions**

Division of Pharmacotherapy and Experimental Therapeutics  
UNC Eshelman School of Pharmacy 2008 - 2016

### **Division Director of Graduate Studies**

Division of Pharmacotherapy and Experimental Therapeutics  
UNC Eshelman School of Pharmacy 2016 - 2017

### **Faculty Director, Research and Scholarship in Pharmacy (RASP) Pathway**

UNC Eshelman School of Pharmacy 2016 - present

### **Vice Chair, Research and Graduate Education (Interim)**

Division of Pharmacotherapy and Experimental Therapeutics  
UNC Eshelman School of Pharmacy 2019 - present

## **UNC Center/Program Affiliations**

UNC McAllister Heart Institute 2006 - present

UNC Nutrition Obesity Research Center 2007 - present

UNC Program for Pharmacogenomics and Individualized Therapy 2009 - present

## **Career Development**

Bill and Karen Campbell Junior Faculty Mentoring Program  
UNC Eshelman School of Pharmacy 2006 - 2011

Faculty Administrator Development Program  
UNC Center for Faculty Excellence 2015 - 2016

## **HONORS / AWARDS**

Ruth L. Kirschstein Individual National Research Service Award, NIH/NIEHS 2003 - 2006

Postdoctoral Award for Research Excellence, UNC-Chapel Hill 2005 - 2006

Elizabeth Barrett-Connor Research Award in Epidemiology 2005

for Young Investigators, AHA Council on Epidemiology and Prevention

Junior Investigator Award, American College of Clinical Pharmacy, 2011

Cardiology Practice and Research Network

Fellow, American College of Clinical Pharmacy (FCCP) 2011

Tenure, University of North Carolina at Chapel Hill 2012

Fellow, American Heart Association, Council on Clinical Cardiology (FAHA) 2015

## **PUBLICATIONS**

(*h*-index: 34, Scopus)

**Manuscripts** (\*corresponding author; #equal contribution) [MyNCBI](#), [Google Scholar](#), [ORCID](#)

1. **Lee CR**, Pieper JA. Low-molecular-weight heparin therapy in acute coronary syndromes. *Hosp Pharm*. 2000;35(9):955-63. [[citation](#)]
2. **Lee CR**, Thrasher KA. Difficulties in anticoagulation management during co-administration of warfarin and rifampin. *Pharmacotherapy*. 2001;21(10):1240-46. [[PMID: 11601670](#)]
3. **Lee CR**, Adams KF, Patterson JH. Surrogate endpoints in heart failure. *Ann Pharmacother*. 2002;36(3):479-88. [[PMID: 11895063](#)]
4. **Lee CR**, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the *in vitro* and human data. *Pharmacogenetics*. 2002;12(4):251-63. [[PMID: 11927841](#)]
5. **Lee CR**, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Evaluation of CYP2C9 metabolic activity with tolbutamide in *CYP2C9\*1* heterozygotes. *Clin Pharmacol Ther*. 2002;72(5):562-71. [[PMID: 12426520](#)]
6. **Lee CR**, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen and losartan as probes of CYP2C9 activity in humans. *J Clin Pharmacol*. 2003;43(1):84-91. [[PMID: 12520632](#)]
7. \***Lee CR**, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Differences in flurbiprofen pharmacokinetics between *CYP2C9\*1/\*1*, *\*1/\*2*, and *\*1/\*3* genotypes. *Eur J Clin Pharmacol*. 2003;58(12):791-94. [[PMID: 12698304](#)]
8. \***Lee CR**, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9\*1/\*1, \*1/\*2, and \*1/\*3 individuals. *Pharmacotherapy*. 2003;23(6):720-25. [[PMID: 12820813](#)]
9. **Lee CR**, Watkins ML, Patterson JH, Adams KF. Vasopressin: a new target for the treatment of heart failure. *Am Heart J*. 2003;146(1):9-18. [[PMID: 12851603](#)]
10. \***Lee CR**. *CYP2C9* genotype as a predictor of drug disposition in humans. *Methods Find Exp Clin Pharmacol*. 2004;26(6):463-72. [[PMID: 15349140](#)]
11. Ng TMH, Carter O, Guillory GS, Howard PA, **Lee CR**, Rodgers JE, Uber PA, Wiggins BS, Munger MA, Patterson JH. High-impact articles related to the pharmacotherapeutic management of systolic heart failure. *Pharmacotherapy*. 2004;24(11):1594-1633. [[PMID: 15537564](#)]
12. Terra SG, Pauly DF, **Lee CR**, Patterson JH, Adams KF, Schofield RS, Hamilton KK, Aranda JM, Hill JA, Yarandi HN, Johnson JA. Effect of beta-adrenergic receptor polymorphisms on the tolerability of metoprolol CR/XL in patients with heart failure. *Clin Pharmacol Ther*. 2005;77(3):127-37. [[PMID: 15735607](#)]
13. Terra SG, Hamilton KK, Pauly DF, **Lee CR**, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hill JA, Aranda JM, Yarandi HN, Johnson JA. Beta-1 adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. *Pharmacogenet Genomics*. 2005;15(4):227-34. [[PMID: 15864115](#)]
14. \***Lee CR**, Hawke RL, Pieper JA. Twenty-four hour tolbutamide plasma concentrations as a phenotypic measure of CYP2C9 activity in humans. *Eur J Clin Pharmacol*. 2005;61(4):315-16. [[PMID: 15875171](#)]
15. Adams KF, Patterson JH, Gattis WA, O'Connor CM, **Lee CR**, Schwartz TA, Gheorghide M. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group Trial: a retrospective analysis. *J Am Coll Cardiol*. 2005;46(3):497-504. [[PMID: 16053964](#)]

16. Fornage M, **Lee CR**, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E. Sequence variation in the soluble epoxide hydrolase gene is associated with ischemic stroke. *Hum Mol Genet.* 2005;14(19):2829-37. [[PMID: 16115816](#)]
17. **Lee CR**, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (*EPHX2*) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. *Hum Mol Genet.* 2006;15(10):1640-49. [[PMID: 16595607](#)] [[NIH Press Release](#)]
18. Seubert JM, Sinal CJ, Graves JP, DeGraff LM, Bradbury, JA, **Lee CR**, Goralski K, Carey MA, Lauria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. *Circ Res.* 2006;99(4):442-50. [[PMID: 16857962](#)]
19. **Lee CR**, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Coresh J, Folsom AR, Boerwinkle E, Heiss G, Zeldin DC. *NOS3* polymorphisms, cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities (ARIC) study. *Pharmacogenet Genomics.* 2006;16(12):891-99. [[PMID: 17108813](#)]
20. **Lee CR**, Bottone FG, Krahn JM, Li L, Mohrenweiser HW, Cook ME, Petrovich RM, Bell DA, Eling TE, Zeldin DC. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (*PTGS1*). *Pharmacogenet Genomics.* 2007;17(2):145-60. [[PMID: 17301694](#)]
21. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. *CYP2J2* and *CYP2C8* polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. *Pharmacogenet Genomics.* 2007;17(5):349-58. [[PMID: 17429317](#)]
22. Dumas T, Hawke RL, \***Lee CR**. Warfarin dosing and the promise of pharmacogenomics. *Curr Clin Pharmacol.* 2007;2(1):11-21. [[PMID: 18690851](#)]
23. Alla F, Al-Hindi AY, **Lee CR**, Schwartz TA, Patterson JH, Adams KF. Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. *Am Heart J.* 2007;153(6):1074-80. [[PMID: 17540212](#)]
24. Yang S, Lin L, Chen JX, **Lee CR**, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, Lu ZY, Wang DW, Zeldin DC. Cytochrome P450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor- $\alpha$  via MAPK and PI3K/Akt signaling pathways. *Am J Physiol Heart Circ Physiol.* 2007;293(1):H142-H151. [[PMID: 17322420](#)]
25. Theken KN, \***Lee CR**. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. *Pharmacogenomics.* 2007;8(10):1369-1383. [[PMID: 17979511](#)]
26. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. *Clin Pharmacol Ther.* 2008;83(1):52-60. [[PMID: 17495879](#)]
27. Jackevicius CA, Page RL, Chow S, Dunn SP, **Lee CR**, Ng TMH, Rodgers JE, Vardeny O, Wiggins BS, Munger MA. High-impact articles related to the management of heart failure: 2008 update. *Pharmacotherapy.* 2009;29(1):82-112. [[PMID: 19113799](#)]
28. Aquilante CL, Beitelshes AL, Cavallari LH, **Lee CR**, Maciejewski S, Momary K, Vardeny O, Zineh I. Key articles relative to cardiovascular pharmacogenomics. *Pharmacotherapy.* 2009;29(9):1110-51. [[citation](#)]
29. Ellis K, Stouffer GA, McLeod HL, \***Lee CR**. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. *Pharmacogenomics.* 2009;10(11):1799-1817. [[PMID: 19891556](#)]
30. Bass A, Hinderliter AL, \***Lee CR**. The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. *Ann Pharmacother.* 2009;43(12):2021-30. [[PMID: 19920161](#)]

31. Deng Y, Theken KN, \*Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. *J Mol Cell Cardiol.* 2010;48(2):331-41. [PMID: 19891972]
32. #Lee CR, #Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. *FASEB J.* 2010;24(10):3770-81. [PMID: 20495177] (NIH Press Release) (The FASEB Journal Press Release)
33. Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, \*Lee CR. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. *Drug Metab Dispos.* 2011;39(1):22-29. [PMID: 20947618]
34. \*Lee CR, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, Brown NJ. Genetic variation in soluble epoxide hydrolase (*EPHX2*) is associated with forearm vasodilator responses in humans. *Hypertension.* 2011;57(1):116-22. [PMID: 21098312]
35. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, DeGraff LM, Lih FB, Foley J, Bradbury JA, Graves JP, Tomer KB, Falck JR, Zeldin DC, \*Lee CR. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. *FASEB J.* 2011;25(2):703-13. [PMID: 21059750]
36. Edin ML, Wang ZJ, Bradbury JA, Graves JP, Lih FB, DeGraff LM, Foley JF, Torphy R, Ronnekleiv OK, Tomer KB, Lee CR, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. *FASEB J.* 2011;25(10):3436-47. [PMID: 21697548]
37. #Panigrahy D, #Edin ML, #Lee CR, #Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio J, Pietramaggiore G, Scherer-Pietramaggiore SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthathi VM, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC. Epoxy-eicosanoids stimulate multi-organ metastasis and tumor dormancy escape in mice. *J Clin Invest.* 2012;122(1):178-91. [PMID: 22182838] (NIH Press Release)
38. \*Lee CR, Bass A, Ellis K, Tran B, Steele S, Caughey M, Stouffer GA, Hinderliter AL. Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers. *Am J Cardiol.* 2012;109(5):651-57. [PMID: 22154090]
39. Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, \*Lee CR. Enalapril reverses high fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. *Am J Physiol Endocrinol Metab.* 2012;302(5):E500-9. [PMID: 22185841]
40. Theken KN, Schuck RN, Edin ML, Tran B, Ellis K, Bass A, Lih FB, Tomer KB, Poloyac SM, Wu MC, Hinderliter AL, Zeldin DC, Stouffer GA, \*Lee CR. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. *Atherosclerosis.* 2012;222(2):530-6. [PMID: 22503544]
41. #Marczak ED, #Marzec J, Zeldin DC, Kleeberger SR, Brown NJ, Pretorius M, \*Lee CR. Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans. *Pharmacogenet Genomics.* 2012; 22(8):620-8. [PMID: 22668754]
42. Li R, Xu X, Chen C, Yu X, Edin ML, DeGraff LM, Lee CR, Zeldin DC, Wang DW. Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. *Prostaglandins Other Lipid Mediat.* 2012; 99(3-4):68-78. [PMID: 23041291]

43. Schuck RN, Theken KN, Edin ML, Caughey M, Bass A, Ellis K, Tran B, Steele S, Simmons BP, Lih FB, Tomer KB, Wu MC, Hinderliter AL, Stouffer GA, Zeldin DC, \***Lee CR**. Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. *Atherosclerosis*. 2013; 227(2):442-8. [[PMID: 23466098](#)]
44. Zhang W, Davis CM, Edin ML, **Lee CR**, Zeldin DC, Alkayed NJ. Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. *PLoS One*. 2013; 8(4):e61244. [[PMID: 23585883](#)]
45. #Oni-Orisan A, #Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, \***Lee CR**. Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. *Prostaglandins Other Lipid Mediat*. 2013; 104-105:67-73. [[PMID: 23000418](#)]
46. Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, Edin ML, **Lee CR**, Benny O, Mudge DR, Butterfield CE, Mammoto A, Mammoto T, Inceoglu B, Jenkins RL, Simpson M, Akino T, Lih FB, Tomer KB, Ingber DE, Hammock BD, Falck JR, Manthati VL, Kaipainen A, D'Amore PA, Puder M, Zeldin DC, Kieran MW. Epoxy-eicosanoids promote organ and tissue regeneration. *Proc Natl Acad Sci U S A*. 2013; 110(33):13528-33. [[PMID: 23898174](#)]
47. Roth MT, Mumper RJ, Singleton SF, **Lee CR**, Rodgers PT, Cox WC, McLaughlin JE, Joyner P, Blouin RA. A renaissance in pharmacy education at the University of North Carolina at Chapel Hill. *N C Med J*. 2014; 75(1):48-52. [[PMID: 24487762](#)]
48. Cheng J, Edin ML, Hoopes SL, Li H, Bradbury JA, Graves JP, DeGraff LM, Lih FB, Garcia V, Shaik JS, Tomer KB, Flake GP, Falck JR, **Lee CR**, Poloyac SM, Schwartzman ML, Zeldin DC. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. *FASEB J*. 2014; 28(7):2915-31. [[PMID: 24668751](#)]
49. Oni-Orisan A, Alsaleh N, **Lee CR**, Seubert JM. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. *J Mol Cell Cardiol*. 2014; 74:199-208. [[PMID: 24893205](#)]
50. Zha W, Edin ML, Vendrov KC, Schuck RN, Lih FB, Jat JL, Bradbury JA, DeGraff LM, Hua K, Tomer KB, Falck JR, Zeldin DC, \***Lee CR**. Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids (EETs) in adipogenesis and obesity. *J Lipid Res*. 2014; 55(10):2124-36. [[PMID: 25114171](#)]
51. Abraham NG, Sodhi K, Silvis AM, Vanella L, Favero G, Rezzani R, **Lee CR**, Zeldin DC, Schwartzman ML. CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. *Hypertension*. 2014;64(6):1352-61. [[PMID: 25245389](#)]
52. Schuck RN, Zha W, Edin ML, Gruzdev A, Vendrov KC, Miller TM, Xu Z, Lih FB, DeGraff LM, Tomer KB, Jones HM, Makowski L, Huang L, Poloyac SM, Zeldin DC, \***Lee CR**. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. *PLoS One*. 2014; 9(10):e110162. [[PMID: 25310404](#)]
53. Lee JA, **Lee CR**, Reed BN, Plitt DC, Polasek MJ, Howell LA, Cicci JD, Tasca KE, Weck KE, Rossi JS, Stouffer GA. Implementation and evaluation of a *CYP2C19* genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. *Pharmacogenomics*. 2015; 16(4):303-13. [[PMID: 25823779](#)]
54. Vanella L, Canestraro M, **Lee CR**, Cao J, Zeldin DC, Schwartzman ML, Abraham NG. Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis. *Prostaglandins Other Lipid Mediat*. 2015; 120:139-47. [[PMID: 25908301](#)]



55. Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoschchenko RG, Hanna SK, Ramanathan RK, **Lee CR**, Bae-Jump VL, Gehrig PA, Zamboni WC. Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. *Nanomedicine*. 2015; 11(7):1797-807. [[PMID: 26093057](#)]
56. Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, \***Lee CR**. Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. *J Lipid Res*. 2016; 57(1):109-19. [[PMID: 26555503](#)]
57. Jia J, Davis CM, Zhang W, Edin ML, Jouihan S, Jia T, Bradbury JA, Graves JP, DeGraff LM, **Lee CR**, Ronnekleiv O, Wang R, Xu Y, Zeldin DC, Alkayed NJ. Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium. *Exp Neurol*. 2016; 279:75-85. [[PMID: 26902473](#)]
58. Wells MA, Vendrov KC, Edin ML, Ferslew BC, Zha W, Nguyen BKH, Church RJ, Lih FB, DeGraff LM, Brouwer KLR, Barritt AS, Zeldin DC, \***Lee CR**. Characterization of the cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis. *Prostaglandins Other Lipid Mediat*. 2016; 125:19-29. [[PMID: 27401401](#)]
59. Cavallari LH, **Lee CR**, Duarte JD, Nutescu EA, Weitzel KW, Stouffer GA, Johnson JA. Inpatient models of pharmacogenetic implementation. *Am J Health Syst Pharm*. 2016; 73(23):1944-54. [[PMID: 27864202](#)]
60. Bai X, Mangum KD, Dee RA, Stouffer GA, **Lee CR**, Oni-Orisan A, Patterson WC, Schisler JC, Viera AJ, Taylor JM, Mack CP. Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. *J Clin Invest*. 2017; 127(2):670-80. [[PMID: 28112683](#)]
61. Martin K, **Lee CR**, Farrell TM, Moll S. Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. *Am J Med*. 2017; 130(5):517-24. [[PMID: 28159600](#)]
62. Cavallari LH, Beitelshes AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, **Lee CR**, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA. The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real-world setting. *Clin Transl Sci*. 2017; 10(3):143-6. [[PMID: 28294551](#)]
63. Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, \***Lee CR**. *CYP2C19*-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. *Pharmacogenomics*. 2017; 18(12):1155-66. [[PMID: 28745582](#)]
64. Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, Kashuba ADM, **Lee CR**, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell JR. Precision dosing: public health need, proposed framework, and anticipated impact. *Clin Transl Sci*. 2017; 10:443-54. [[PMID: 28875519](#)]
65. Ravi S, Schuck RN, Hilliard E, **Lee CR**, Dai X, Lenhart K, Willis MS, Jensen BC, Stouffer GA, Patterson C, Schisler JC. Clinical evidence supports a protective role for CXCL5 in coronary artery disease progression in the elderly. *Am J Pathol*. 2017; 187(12):2895-2911. [[PMID: 29153655](#)] ([UNC Health Care News Story](#))
66. Wang N, Vendrov KC, Simmons BP, Schuck RN, Stouffer GA, \***Lee CR**. Urinary 11-dehydrothromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. *Prostaglandins Other Lipid Mediat*. 2018; 134:24-31. [[PMID: 29155368](#)]

67. Cavallari LH, **Lee CR**, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh I, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake D, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA on behalf of the IGNITE Network. Multisite investigation of outcomes with implementation of *CYP2C19* genotype-guided antiplatelet therapy after percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2018; 11(2):181-191. [PMID: 29102571] ([UNC Health Care News Story](#))
68. Seyerle AA, Sitlani CM, Noordam R, Gogarten SM, Li J, Li X, Evans DS, Sun F, Laaksonen MA, Isaacs A, Kristiansson K, Highland HM, Stewart JD, Harris TB, Trompet S, Bis JC, Peloso GM, Brody JA, Broer L, Busch EL, Duan Q, Stilp AM, O'Donnell C, MacFarlane PW, Floyd JS, Kors JA, Lin HJ, Li-Gao R, Sofer T, Mendez-Giráldez R, Cummings SR, Heckbert SR, Hofman A, Ford I, Li Y, Launer LJ, Porthan K, Newton-Cheh C, Napier MD, Kerr KF, Reiner AP, Rice KM, Roach J, Buckley BM, Soliman EZ, de Mutsert R, Sotoodehnia N, Uitterlinden AG, North KE, **Lee CR**, Gundnason V, Stürmer T, Rosendaal FR, Taylor KD, Wiggins KL, Wilson JG, Chen YD, Kaplan RC, Wilhelmsen K, Cupples LA, Salomaa V, van Duijn C, Jukema JW, Liu Y, Mook-Kanamori DO, Lange LA, Vasani RS, Smith AV, Stricker BH, Laurie CC, Rotter JI, Whitsel EA, Psaty BM, Avery CL. Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: The Cohorts for Heart and Aging Research using Genomic Epidemiology (CHARGE). *Pharmacogenomics J.* 2018; 18(2):215-226. [PMID: 28719597]
69. Empey PE, Stevenson J, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshes AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, **Lee CR** on behalf of the IGNITE Network. Multi-site investigation of strategies for the implementation of *CYP2C19* genotype-guided antiplatelet therapy. *Clin Pharmacol Ther.* 2018; 104(4): 664-674. [PMID: 29280137]
70. \***Lee CR**, Sriramoju VB, Cervantes A, Howell LA, Varunok N, Madan S, Hamrick K, Polasek MJ, Lee JA, Clarke M, Cicci JD, Weck KE, Stouffer GA. Clinical outcomes and sustainability of using *CYP2C19* genotype-guided antiplatelet therapy after percutaneous coronary intervention. *Circ Genom Precis Med.* 2018; 11(4):e002069. [PMID: 29615454] ([AHA News Story](#)) ([Science Magazine News Story](#)) ([MedPage Today](#)) ([CV Research Foundation News Story](#))
71. Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, **Lee CR**, Wiltshire T. Projected impact of a multi-gene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. *Pharmacogenomics.* 2018; 19(9):771-82. [PMID: 29793377]
72. Klein MD, **Lee CR**, Stouffer GA. Clinical outcomes of *CYP2C19* genotype-guided antiplatelet therapy: existing evidence and future directions. *Pharmacogenomics.* 2018; 19(13):1039-46. [PMID: 30028231]
73. Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, \***Lee CR**. Association between the *EPHX2* p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. *Prostaglandins Other Lipid Mediat.* 2018; 138:15-22. [PMID: 30096423]
74. Klein MD, Williams AK, **Lee CR**, Stouffer GA. Clinical utility of *CYP2C19* genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention. *Arterioscler Thromb Vasc Biol.* 2019; 39(4):647-52. [PMID: 30760018]



75. Williams AK, Klein MD, Martin J, Weck KE, Rossi JS, Stouffer GA, \***Lee CR**. *CYP2C19* genotype-guided antiplatelet therapy and thirty-day outcomes after percutaneous coronary intervention. *Circ Genom Precis Med*. 2019;12(2):e002441. [[PMID: 30779635](#)]
76. #Khatri R, #Fallon JK, Rementer RJB, Kulick NT, **Lee CR**, Smith PC. Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte model. *J Pharmacol Toxicol Methods*. 2019; 98:106590. [[PMID: 31158457](#)]
77. Martin J, Williams AK, Klein MD, Sriramoju VB, Madan S, Clarke M, Cicci JD, Rossi JS, Cavallari LH, Weck KE, Stouffer GA, \***Lee CR**. Frequency and clinical outcomes of *CYP2C19* genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. *Genet Med*. 2020; 22(1):160-69. [[PMID: 31316169](#)]  
 (“[Top 10 Advances in Genomic Medicine in 2019](#)” by the NIH/NHGRI Genomic Medicine Working Group)
78. Dong OM, Wheeler SB, Cruden G, **Lee CR**, Voora D, Dusetzina SB, Wiltshire T. Cost-effectiveness of multi-gene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention. *Value Health*. 2020; 23(1):61-73. [[PMID: 31952675](#)]
79. Limdi NA, Cavallari LH, **Lee CR**, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshes AL, Empey PE, Duarte JD, Daiby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Cost-effectiveness of *CYP2C19*-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real world data. *Pharmacogenomics J*. 2020; (Feb 11, epub ahead of print). [[PMID: 32042096](#)]
80. Theken KN, **Lee CR**, Gong L, Caudle KE, Formea CM, Agúndez JAG, Grosser T. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2C9* and non-steroidal anti-inflammatory drugs. *Clin Pharmacol Ther*. 2020; (Mar 19, epub ahead of print). [[PMID: 32189324](#)]
81. Black RM, Williams AK, Ratner L, Crona DJ, Wiltshire T, Stouffer GA, \***Lee CR**. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. *Pharmacogenomics*. 2020; 21(7):431-41. [[PMID: 32343201](#)]
82. Gower MN, Ratner L, Williams AK, Rossi JS, Stouffer GA, \***Lee CR**. Clinical utility of *CYP2C19* genotype-guided antiplatelet therapy in patients at risk of adverse cardiovascular and cerebrovascular events: a review of emerging evidence. *Pharmacogenomics Pers Med*. 2020; (in press).

### Letter to the Editor / Invited Editorials

1. **Lee CR**, Zeldin DC. The reality of pharmacogenomics: optimizing therapeutic decision making. *Environ Health Perspect*. 2003; 111(11):A566-7. [[PMID: 12928152](#)]
2. \***Lee CR**. Warfarin initiation and the potential role of genomic-guided dosing. *Clin Med Res*. 2005; 3(4):205-6. [[PMID: 16303884](#)]
3. Steele S, \***Lee CR**. Research Highlights: highlights from the latest articles in clopidogrel pharmacogenomics. *Pharmacogenomics*. 2010; 11(12):1687-90. [[citation](#)]
4. Simmons BP, \***Lee CR**. Research Highlights: highlights from the latest articles in personalized cardiovascular medicine. *Per Med*. 2012; 9(4):363-6. [[PMID: 29776257](#)]
5. Lee JA, \***Lee CR**. Highlights from recent advances in antiplatelet pharmacogenomics. *Per Med*. 2014; 11(2):135-8. [[PMID: 29751376](#)]
6. **Lee CR**, Zeldin DC. Clinical Implications of Basic Research: Resolvin infectious inflammation by targeting the host response. *N Engl J Med*. 2015; 373(22):2183-5. [[PMID: 26605933](#)]

7. \***Lee CR**, Stouffer GA. Response by Lee and Stouffer to Letter Regarding "Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention". *Circ Genom Precis Med*. 2018;11(7):e002258. [PMID: [29987116](#)]
8. Cavallari LH, **Lee CR**. A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary intervention. *Future Cardiol*. 2019;15(4):251-4. [PMID: [31385522](#)]
9. Stouffer GA, **Lee CR**. Logistical challenges associated with implementing precision medicine. *JAMA Cardiol*. 2019;4(12):1300. [PMID: [31664434](#)]

### Book Chapters

1. Rodgers JE, **Lee CR**. Chapter 22: Acute Decompensated Heart Failure. In: Dipiro JT, Talbert RL, Yee GC, Matzke G, Wells B, Posey M (eds). *Pharmacotherapy: A Pathophysiologic Approach, Eighth Edition*. New York: The McGraw-Hill Companies, Inc; 2011. Pages 191-207.

### Abstracts (presenting author)

1. **Lee CR**, Pieper JA, Goldstein JA, Blaisdell J, Clarke MJ, Hinderliter AL. Pharmacokinetic and pharmacodynamic consequences of CYP2C9 genetic polymorphisms with losartan. *Pharmacotherapy*. 2001;21(10):1286 [abstract 204]. Presented at the 2001 American College of Clinical Pharmacy Annual Meeting, Tampa Bay, FL, October 22, 2001.
2. **Lee CR**, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Assessment of CYP2C9 phenotypic:genotypic relationships with potential probes. *Clin Pharmacol Ther*. 2002;71(2):25 [abstract MPI-81]. Presented at the 103<sup>rd</sup> American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 25, 2002. "Top Abstract" Recipient.
3. **Lee CR**, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Alterations in tolbutamide disposition in CYP2C9\*1 heterozygotes. *Clin Pharmacol Ther*. 2002;71(2):30 [abstract MPI-98]. Presented at the 103<sup>rd</sup> American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 25, 2002.
4. **Lee CR**, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Consequences of CYP2C9 polymorphisms on flurbiprofen pharmacokinetics. *Clin Pharmacol Ther*. 2002;71(2):62 [abstract TPII-77]. Presented at the 103<sup>rd</sup> American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 26, 2002.
5. Pieper JA, **Lee CR**, Hinderliter AL, Clarke MJ, Blaisdell JA, Goldstein JA. Effect of CYP2C9 genotype on losartan disposition. *Clin Pharmacol Ther*. 2002;71(2):68 [abstract TPII-98]. Presented at the 103<sup>rd</sup> American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 26, 2002.
6. **Shah PJ**, Patterson JH, Gattis WA, Ghali J, **Lee CR**, O'Connor CM, Schwartz TA, Gheorghide M, Adams KF. Risk of death in patients with preserved systolic function: retrospective analysis of the Digitalis Investigational Group (DIG) trial. *J Card Failure*. 2003;9(5 Suppl 1):S85 [abstract 313]. Presented at the 7<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Las Vegas, NV, September 2003.
7. **Lee CR**, Shah PJ, Adams KF, Gattis WA, O'Connor CM, Gheorghide M, Schwartz TA, Patterson JH. Variability in serum digoxin concentrations (SDCs) in the Digitalis Investigational Group (DIG) trial: a retrospective analysis. *Pharmacotherapy*. 2003;23(10):1331 [abstract 22]. Presented at the 2003 American College of Clinical Pharmacy Annual Meeting, Atlanta, GA, November 5, 2003.
8. **Lee CR**, Patterson JH, Gattis WA, Ghali J, Shah PJ, Schwartz TA, Gheorghide M, Adams KF. Renal dysfunction is common in patients with heart failure and preserved systolic function:

retrospective analysis of the Digitalis Investigational Group (DIG) trial. *Circulation*. 2003;108(17):IV-484-5 [abstract 2220]. Presented at the American Heart Association Scientific Sessions 2003, Orlando, FL, November 10, 2003.

9. Terra SG, Hamilton KK, Pauly DF, **Lee CR**, Patterson JH, Adams KF, Schofield RS, Hill JA, Aranda JM, Yarandi HN, Johnson JA. Arg389Gly beta-1 adrenergic receptor polymorphism and left ventricular remodeling changes to beta-blocker therapy. *Clin Pharmacol Ther*. 2004;75(2):P2 [abstract OI-A-4]. Presented at the 105<sup>th</sup> American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Miami, FL, March 2004.
10. Terra SG, Pauly DF, **Lee CR**, Patterson JH, Adams KF, Schofield RS, Hamilton KK, Hill JA, Aranda JM, Johnson JA. Effect of beta-1 adrenergic receptor polymorphisms on the tolerability of metoprolol CR/XL in heart failure. *Clin Pharmacol Ther*. 2004;75(2):P16 [abstract PI-49]. Presented at the 105<sup>th</sup> American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Miami, FL, March 2004.
11. Adams KF, Patterson JH, Gattis WA, O'Connor CM, **Lee CR**, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group (DIG) Trial: A Retrospective Analysis. *J Card Failure*. 2004;10(4):S23. Presented at the 8<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Toronto, Canada, September 13, 2004.
12. **Lee CR**, Patterson JH, Gattis WA, O'Connor CM, Schwartz TA, Gheorghiade M, Adams KF. Renal function, independent of ejection fraction and heart size, is a predictor of mortality in patients with heart failure and preserved ejection fraction: a retrospective analysis of the Digitalis Investigational Group (DIG) Trial. *J Card Failure*. 2004;10(4):S87. Presented at the 8<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Toronto, Canada, September 13, 2004.
13. Patterson JH, **Lee CR**, Gheorghiade M, Gattis WA, O'Connor CM, Schwartz TA, Adams KF. Clinical severity predicts response to digoxin: a retrospective analysis of the Digitalis Investigational Group (DIG) Trial. *J Card Failure*. 2004;10(4):S87. Presented at the 8<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Toronto, Canada, September 2004.
14. Alla FM, Patterson JH, Gattis WA, O'Connor CM, **Lee CR**, Schwartz TA, Gheorghiade M, Adams KF. Women with preserved systolic function have better survival than men: retrospective analysis of the Digitalis Investigational Group (DIG) Trial. *J Card Failure*. 2004;10(4):S90. Presented at the 8<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Toronto, Canada, September 14, 2004.
15. **Lee CR**, Pieper JA, Hawke RL, Hinderliter AL, Blaisdell JA, Goldstein JA. Twenty-four hour tolbutamide plasma concentrations as a phenotypic measure of CYP2C9 activity in humans. *Pharmacotherapy*. 2004;24(10):1469 [abstract 261]. Presented at the 2004 American College of Clinical Pharmacy Annual Meeting, Dallas, TX, October 25, 2004.
16. North KE, Mosher MJ, Avery CL, Coresh J, Boerwinkle E, Zeldin DC, **Lee CR**, Couper D, Bray MS. Endothelial nitric oxide synthase (eNOS) Glu298Asp polymorphism association with coronary heart disease risk is modified by smoking: the Atherosclerosis Risk in Communities Study. *Circulation*. 2004;110(17):III-823 [abstract 3800]. Presented at the American Heart Association Scientific Sessions 2004, New Orleans, LA, November, 2004.
17. Al-Hindi AY, **Lee CR**, Schwartz TA, Patterson JH, Alla FM, Adams KF. Chest X-ray predicts outcome in heart failure patients with preserved and reduced ejection fraction: analysis from the Digitalis Investigation Group (DIG) Trial. *J Card Failure*. 2005;11(6):S170. Presented at the 9<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Boca Raton, FL, September 19, 2005.

18. Al-Hindi AY, **Lee CR**, Patterson JH, Schwartz TA, Alla FM, Adams KF. Signs but not symptoms predict outcome in heart failure with preserved and reduced ejection fraction: analysis from the Digitalis Investigation Group (DIG) Trial. *J Card Failure*. 2005;11(6):S173. Presented at the 9<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Boca Raton, FL, September 19, 2005.
19. **Lee CR**, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Heiss G, Zeldin DC. Genetic variation in endothelial nitric oxide synthase (*NOS3*) and risk of coronary heart disease: an Atherosclerosis Risk in Communities (ARIC) study. *Pharmacotherapy*. 2005;25(10):1479 [abstract 292]. Presented at the 2005 American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 24, 2005.
20. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Genetic variation in cyclooxygenase-1 (*PTGS1*) and risk of ischemic stroke: an Atherosclerosis Risk in Communities (ARIC) study. *Pharmacotherapy*. 2005;25(10):1479 [abstract 293]. Presented at the 2005 American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 24, 2005. "Best Poster Award" Finalist.
21. Alla FM, Al-Hindi AY, **Lee CR**, Schwartz TA, Patterson JH, Adams KF. Women have reduced risk for hospitalization in heart failure due to left ventricular dysfunction but not preserved ejection fraction: retrospective analysis of the Digitalis Investigation Group (DIG) Trial. *Circulation*. 2005;112(17):II-410 [abstract 1996]. Presented at the American Heart Association Scientific Sessions 2005, Dallas, TX, November 14, 2005.
22. **Lee CR**, North KE, Bray MS, Fornage M, Seubert JM, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (*EPHX2*) and risk of coronary heart disease: an Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. 2005;112(17):II-821 [abstract 3801]. Presented at the American Heart Association Scientific Sessions 2005, Dallas, TX, November 15, 2005. "Elizabeth Barrett-Connor Research Award in Epidemiology for Young Investigators" winner.
23. Adams KF, Patterson JH, Stough WG, Alla FM, O'Connor CM, **Lee CR**, Schwartz TA, Gheorghide M. Relationship of clinical signs and chest X-ray congestion to the efficacy of digoxin in patients with chronic heart failure: a retrospective analysis from the Digitalis Investigation Group (DIG) Trial. *J Card Failure*. 2006;12(6):S87-88 [abstract 282]. Presented at the 10<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Seattle, WA, September 2006.
24. Alla FM, Al-Hindi AY, **Lee CR**, Schwartz TA, Patterson JH, Ghali JK, Adams KF. Diabetes reduces the likelihood of more favorable outcomes in women than men with heart failure: a retrospective analysis from the Digitalis Investigation Group (DIG) Trial. *J Card Failure*. 2006;12(6):S94 [abstract 303]. Presented at the 10<sup>th</sup> Heart Failure Society of America Annual Scientific Meeting, Seattle, WA, September 2006.
25. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. The G-765C promoter polymorphism in cyclooxygenase-2 (*PTGS2*), aspirin utilization and cardiovascular disease risk: the Atherosclerosis Risk in Communities (ARIC) Study. *Pharmacotherapy*. 2006;26(suppl):e87 [abstract 227]. Presented at the 2006 American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 27, 2006.
26. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Genetic variation in *CYP2J2* and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. 2006;114(18):II-490 [abstract 2386]. Presented at the American Heart Association Scientific Sessions 2006, Chicago, IL, November 13, 2006.
27. Imig JD, **Lee CR**, Bradbury JA, Graves JP, DeGraff LM, Foley J, Zeldin DC. *CYP2J2* endothelial overexpression increases nitric oxide and cyclooxygenase independent renal dilation and attenuates endothelin-1 vasoconstriction. *Circulation*. 2007;116:II-295-296

[abstract 1436]. Presented at the American Heart Association Scientific Sessions 2007, Orlando, FL, November 7, 2007.

28. Bass A, Caughey M, Hull JH, Stouffer GA, Hinderliter AL, **Lee CR**. Phenotypic characterization of endothelial function in individuals with established atherosclerosis using two non-invasive methods. *Pharmacotherapy*. 2008;28(10):120 [abstract 19]. Presented at the 2008 American College of Clinical Pharmacy Annual Meeting, Louisville, KY, October 21, 2008. "Best Resident and Fellow Poster Award" Finalist.
29. Jia J, **Lee CR**, DeGraff LM, Bradbury JA, Zeldin DC, Alkayed NJ. P450 epoxygenase overexpression in vascular endothelium alters blood flow and infarct size after middle cerebral artery occlusion in a sex- and isoform-specific manner. *Stroke*. 2009;40(4):45 [abstract 187]. Presented at the International Stroke Conference 2009, San Diego, CA, February 20, 2009.
30. **Lee CR**, Bass A, Ellis K, Caughey M, Stouffer GA, Hinderliter AL. Relationships between peripheral arterial tonometry and brachial artery ultrasound measures of endothelial function in patients with established atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2009;29(7):e55-56 [abstract P244]. Presented at Arteriosclerosis, Thrombosis, and Vascular Biology 2009 Scientific Sessions. Washington D.C., April 29, 2009.
31. Deng Y, Theken KN, Edin ML, Kannon MA, Schuck RN, DeGraff L, Bradbury JA, Graves J, Zeldin DC, **Lee CR**. Endothelial CYP2J2 and CYP2C8 over-expression and soluble epoxide hydrolase deletion attenuate acute inflammatory responses in mice. *Arterioscler Thromb Vasc Biol*. 2009;29(7):e63 [abstract P286]. Presented at Arteriosclerosis, Thrombosis, and Vascular Biology 2009 Scientific Sessions. Washington D.C., April 30, 2009.
32. Ellis K, Bass A, Theken KN, Caughey M, Burch LH, Brown NJ, Zeldin DC, Stouffer GA, Hinderliter AL, **Lee CR**. Cyclooxygenase-2 and endothelial nitric oxide synthase polymorphisms and endothelial function in coronary artery disease patients. *Pharmacotherapy*. 2009;29(10):232e [abstract 176]. Presented at the 2009 American College of Clinical Pharmacy Annual Meeting, Anaheim, CA, October 21, 2009.
33. Ellis K, Bass A, Tran B, Caughey M, Stouffer GA, Hinderliter AL, **Lee CR**. Evaluation of endothelial function using peripheral arterial tonometry in coronary artery disease patients treated for depression. *Pharmacotherapy*. 2010;30(4):180e [abstract 107]. Presented at the 2010 American College of Clinical Pharmacy Spring Practice and Research Forum, Charlotte, NC, April 26, 2010.
34. **Lee CR**, Pretorius M, Schuck RN, Burch LH, Williams SM, Zeldin DC, Brown NJ. Genetic variation in soluble epoxide hydrolase is associated with vascular responsiveness to bradykinin in humans. *Hypertension*. 2010;56(5):e148 [abstract P447]. Presented at the American Heart Association High Blood Pressure Research 2010 Scientific Sessions, Washington, DC, October 15, 2010.
35. **Lee CR**, Tran B, Ellis K, Bass A, Caughey M, Stouffer GA, Hinderliter AL. Relationships between digital peripheral arterial tonometry and brachial artery velocity measures of endothelial function in humans. *Hypertension*. 2010;56(5):e150 [abstract P457]. Presented at the American Heart Association High Blood Pressure Research 2010 Scientific Sessions, Washington, DC, October 15, 2010.
36. Tran B, Ellis K, Bass A, Caughey M, Theken KN, Schuck RN, Stouffer GA, Hinderliter AL, **Lee CR**. Evaluation of peripheral arterial tonometry in coronary artery disease patients and healthy volunteers. *Pharmacotherapy*. 2010;30(10):444e [abstract 280]. Presented at the 2010 American College of Clinical Pharmacy Annual Meeting, Austin, TX, October 2010.
37. Theken KN, Deng Y, Schuck RN, Kannon MA, Miller TM, Poloyac SM, **Lee CR**. High-fat diet suppresses hepatic cytochrome P450-mediated eicosanoid metabolism in mice. *AAPS J*. 2010; 12(S2) [abstract W4325]. Presented at the International Pharmaceutical Federation Pharmaceutical Sciences World Congress/American Association of Pharmaceutical



Scientists Annual Meeting, New Orleans, LA, November 2010.

38. Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, **Lee CR**. Lipopolysaccharide suppresses hepatic and extra-hepatic cytochrome P450 expression and arachidonic acid-metabolizing activity in mice. *AAPS J.* 2010; 12(S2) [abstract W4326]. Presented at the International Pharmaceutical Federation Pharmaceutical Sciences World Congress/American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, November 2010.
39. Schuck RN, Theken KN, Edin ML, Caughey M, Tran B, Steele S, Ellis K, Bass A, Lih FB, Tomer KB, Zeldin DC, Stouffer GA, Hinderliter AL, **Lee CR**. Inverse correlation between plasma 20-Hydroxyeicosatetraenoic acid levels and endothelial function in patients with hypertension and coronary artery disease. *Arterioscler Thromb Vasc Biol.* 2011; [abstract P388]. Presented at Arteriosclerosis, Thrombosis, and Vascular Biology 2011 Scientific Sessions, Chicago, IL, April 2011.
40. Steele S, Tran B, Ellis K, Bass A, Schuck RN, Caughey M, Stouffer GA, Hinderliter AL, **Lee CR**. Endothelial nitric oxide synthase polymorphisms and endothelial function in coronary artery disease patients. *Pharmacotherapy.* 2011;31(10):e371-2 [abstract 220]. Presented at the Great Eight Session, 2011 American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA, October 16, 2011. "Best Poster Award" Finalist.
41. Simmons BP, Schuck RN, Molnar K, Steele S, Caughey M, Hinderliter AL, Stouffer GA, **Lee CR**. Thromboxane and prostaglandin metabolite levels and inflammation phenotypes in coronary artery disease patients. *Pharmacotherapy.* 2012;32(10):e189 [abstract 39]. Presented at the 2012 American College of Clinical Pharmacy Annual Meeting, Hollywood, FL, October 22, 2012. "Best Resident and Fellow Poster Award" Finalist.
42. Reed BR, Wittorf R, Plitt DC, Weck KE, **Lee CR**, Stouffer GA. Influence of clinical and genetic characteristics on P2Y12 inhibitor selection in high-risk patients with coronary artery disease. *Pharmacotherapy.* 2013;33(10):e191 [abstract 30]. Presented at the 2013 American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM, October, 2013.
43. Bai X, Stouffer GA, **Lee CR**, Schisler J, Patterson C, Lee JA, Oni-Orisan A, Mack CP, Taylor, JM. The smooth muscle-selective RhoGAP Graf3 is a critical regulator of vascular tone and hypertension. *Hypertension.* 2014;64(Suppl1):A627 [abstract 627]. Presented at the American Heart Association High Blood Pressure Research 2014 Scientific Sessions, San Francisco, CA, September, 2014.
44. Lee JA, Reed BN, Plitt DC, Cicci JD, Tasca K, Weck KE, **Lee CR**, Stouffer GA. Implementation and evaluation of a *CYP2C19* genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. *Pharmacotherapy.* 2014;34(10):e221 [abstract #171]. Presented at the 2014 American College of Clinical Pharmacy Annual Meeting. Austin, TX, October 15, 2014. "M. Kelli Jordan Pharmacokinetics-Dynamics-Genomics Practice Research Network Travel Award" Winner.
45. Oni-Orisan A, Theken KN, Schuck RN, Edin ML, Hinderliter AL, Stouffer GA, Zeldin DC, **Lee CR**. Initial characterization of cytochrome P450-derived eicosanoids as a predictive biomarker in coronary artery disease. *Pharmacotherapy.* 2014;34(10):e187 [abstract #32]. Presented at the 2014 American College of Clinical Pharmacy Annual Meeting, Austin, TX, October 13, 2014. "Best Resident and Fellow Poster Award" Winner.
46. Oni-Orisan A, Edin ML, Lee JA, Stouffer GA, Zeldin DC, **Lee CR**. Characterization of the relationship between biomarkers of cytochrome P450-mediated eicosanoid metabolism and coronary artery disease severity in humans. *Clin Pharmacol Ther.* 2015;97(S1):S13 [abstract #PT-07, OIII-4]. Presented at the 2015 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, LA, March 4, 2015. "[Presidential Trainee Award](#)" winner.

47. Wells MA, Vendrov KC, Edin ML, Ferslew BC, Brouwer KLR, Barritt AS, Zeldin DC, **Lee CR**. Translational evaluation of the relationship between biomarkers of cytochrome P450-mediated eicosanoid metabolism and non-alcoholic steatohepatitis (NASH). *Clin Pharmacol Ther.* 2016;99(S1):S82 [abstract #PII-026]. Presented at the 2016 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, San Diego, CA, March 11, 2016.
48. Schisler JC, Schuck RN, Dai X, Lenhart K, **Lee CR**, Stouffer GA, Patterson C. Clinical evidence of a protective role for CXCL5 in coronary artery disease progression in the elderly. *FASEB J.* 2016;30(S1):1117.17. Presented at Experimental Biology 2016. San Diego, CA. April 5, 2016.
49. Varunok N, Hamrick K, Polasek MJ, Lee JA, Wells MA, Cervantes A, Sriramoju VB, Howell L, Stouffer GA, **Lee CR**. Clinical and genetic predictors of anti-platelet therapy selection in coronary artery disease patients undergoing percutaneous coronary intervention. *Pharmacotherapy.* 2016;36(7):e113 [abstract #102]. Presented at the 2016 American College of Clinical Pharmacy Virtual Poster Symposium. May 18, 2016.
50. Sriramoju VB, Varunok N, Howell LA, Cervantes A, Polasek MJ, Stouffer GA, **Lee CR**. Risk factors for bleeding modify the impact of *CYP2C19* genetic test results on antiplatelet drug selection. *Circulation.* 2016;134(Suppl 1): A16889 [abstract #16889]. Presented at American Heart Association 2016 Scientific Sessions, New Orleans, LA, November 15, 2016.
51. Cavallari LH, Denny JC, **Lee CR**, Beitelshes AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, Gong Y, Wei W, Pratt VM, Chumnumwat S, Coons JC, Cooper-DeHoff RM, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Empey PE, Kreutz RP, Stouffer GA, Wilke RA, Limdi NA, Roden DM, Shuldiner AR, Johnson JA, Peterson JF. Prospective clinical implementation of *CYP2C19*-genotype guided antiplatelet therapy after PCI: a multi-site investigation of MACE outcomes in the real world setting. *Circulation.* 2016;134(25):e711 [abstract #21050]. Presented at American Heart Association 2016 Scientific Sessions as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines, New Orleans, LA, November 15, 2016. ([NIH Press Release](#)) ([UNC News Story](#))
52. Cervantes A, Sriramoju VB, Varunok N, Hamrick K, Stouffer GA, **Lee CR**. Utilization of a *CYP2C19* genotype-guided antiplatelet treatment algorithm over time in patients undergoing percutaneous coronary intervention. *Pharmacotherapy.* 2017;37(6):e56 [abstract #76]. Presented at the 2017 American College of Clinical Pharmacy Virtual Poster Symposium. May 17, 2017. "Best Poster Award" Winner.
53. Dong O, Li A, Suzuki O, Oni-Orisan A, Stouffer GA, **Lee CR**, Wiltshire T. Projected impact of adopting a multiplexed preemptive genotyping intervention in cardiac catheterization laboratory patients. *Value Health.* 2017;20(5):A276 [abstract #PCV95]. Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22<sup>nd</sup> Annual International Meeting. Boston, MA. May 23, 2017.
54. Seyerle AA, Sitlani CM, North KE, **Lee CR**, Whitsel EA, Stürmer T, Avery CL. Effect of bias and exposure misclassification on gene-environment studies conducted in observational cohort settings: a simulation study. *Genet Epidemiol.* 2017; 41(7):688 [abstract #122]. Presented at 2017 Annual Meeting of the International Genetic Epidemiology Society. Cambridge, UK, September 9, 2017.
55. **Lee CR**, Sriramoju VB, Cervantes A, Varunok N, Howell LA, Madan S, Weck KE, Stouffer GA. Evaluation of cardiovascular outcomes following implementation of *CYP2C19* genotype-guided antiplatelet therapy in a real-world clinical setting. *Circulation.* 2017; 136 (Suppl 1): A16575 [abstract #16575]. Presented at American Heart Association 2017 Scientific Sessions, Anaheim, CA, November 14, 2017.

56. Dong OM, Borse MS, Polasek MJ, Farley JF, Stouffer GA, **Lee CR**. *CYP2C19* guided antiplatelet therapy: a cost-effectiveness analysis of 30 day and one year outcomes following percutaneous coronary intervention. *Value Health*. 2017;20(9):A405 [abstract #CV3]. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20<sup>th</sup> Annual European Congress. Glasgow, Scotland. November 6, 2017.
57. Empey PE, Stevenson J, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshes AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Obeng AO, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, **Lee CR**. Multi-site investigation of strategies for the implementation of *CYP2C19* genotype-guided antiplatelet therapy. *Clin Pharmacol Ther*. 2018;103(S1):S31-32 [abstract #PI-066]. Presented at the 2018 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 22, 2018.
58. Klein M, Sriramoju VB, Cervantes A, Varunok N, Madan S, Weck KE, **Lee CR**, Stouffer GA. Thirty day clinical outcomes following implementation of *CYP2C19* genotype-guided dual antiplatelet therapy. *J Am Coll Cardiol*. 2018;71(11):1196 [abstract #1194-223]. Presented at 2018 American College of Cardiology Scientific Sessions, Orlando, FL, March 11, 2018.
59. Dong OM, **Lee CR**, Wheeler S, Voora D, Dusetzina S, Wiltshire T. A cost-effectiveness analysis of multi-gene pharmacogenetic testing in acute coronary syndrome patients following percutaneous coronary intervention. *Value Health*. 2018;21(S3):S6 [abstract #CV1]. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21<sup>st</sup> Annual European Congress. Barcelona, Spain. November 13, 2018. "Best Student Podium Research Presentation" winner.
60. Martin J, Williams AK, Klein MD, Sriramoju VB, Madan S, Rossi JS, Stouffer GA, **Lee CR**. *CYP2C19* genotype-guided escalation and de-escalation switching of antiplatelet therapy after percutaneous coronary intervention in a real-world setting. *Clin Pharmacol Ther*. 2019;105(S1):S23 [abstract #PT-002]. Presented at the 2019 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Washington, DC, March 13, 2019. "[Presidential Trainee Award](#)" and "Jason Morrow Trainee Award" winner.
61. Morbitzer KA, McLaughlin JE, Olsen A, Zhang Q, Dumond J, Carpenter D, Ozawa S, Smith P, Bush A, Pomykal C, **Lee CR**. Implementation and initial evaluation of an innovative approach to research and scholarship training in pharmacy education. *JACCP*. 2020;3(1):193 [abstract #108]. Presented at the 2019 American College of Clinical Pharmacy Annual Meeting, New York, NY. October 25, 2019.
62. Smith S, Khatri R, Kulick N, Rementer R, Dorman KF, Boggess KA, **Lee CR**. Initial characterization of nicotinamide metabolism in pregnancy: a novel treatment for preeclampsia. *JACCP*. 2020;3(1):276 [abstract #295]. Presented at the 2019 American College of Clinical Pharmacy Annual Meeting, New York, NY. October 26, 2019.
63. Gower MN, Williams AK, Gustafson C, Pauley E, Weck KE, Stouffer GA, **Lee CR**. Evaluation of cardiovascular outcomes in African-Americans following implementation of *CYP2C19* genotype-guided antiplatelet therapy in a real-world setting. *Clin Pharmacol Ther*. 2020; 107(S1):S58 [abstract # PII-084]. 2020 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Houston, TX, March 2020. "Top Abstract" Recipient.
64. Gustafson CE, Williams AK, Pauley E, Weck KE, **Lee CR**, Stouffer GA. Effect of gender on clinical outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. *J Am Coll Cardiol*. 2020; 75(11 Suppl 1):1339 [abstract # 1254-047]. Presented at 2020 American College of Cardiology ACC.20/WCC Virtual Conference, March 28, 2020.

### Meeting Proceedings (presenting author)

1. **Lee CR**, Bottone FG, Bray MS, North KE, Cook ME, Petrovich RM, Heiss G, Eling TE, Zeldin DC. *Genetic polymorphisms in cyclooxygenase-1 (PTGS1): functional characterization and association with cardiovascular disease risk*. 8<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2006. "Travel Award" recipient.
2. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. *The G-765C promoter polymorphism in cyclooxygenase-2 (PTGS2), aspirin utilization and cardiovascular disease risk: The Atherosclerosis Risk in Communities (ARIC) study*. 9<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2007.
3. **Theken KN**, Deng Y, Kannon MA, DeGraff L, Graves J, Zeldin DC, **Lee CR**. *In vivo effects of acute inflammation on cardiovascular cytochrome P450 and EPHX2 expression in mice*. 10<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2008.
4. **Deng Y**, Theken KN, Edin ML, Kannon MA, DeGraff L, Bradbury JA, Zeldin DC, **Lee CR**. *Endothelial CYP2J2 and CYP2C8 overexpression attenuates lipopolysaccharide-induced adhesion molecule expression in mice*. 10<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2008. "Travel Award" recipient.
5. **Deng Y**, Theken KN, Edin ML, Kannon MA, Schuck RN, DeGraff L, Bradbury JA, Graves J, Zeldin DC, **Lee CR**. *Endothelial CYP2J2 and CYP2C8 overexpression and soluble epoxide hydrolase deletion attenuate acute inflammatory responses in mice*. 11<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2009.
6. **Theken KN**, Deng Y, Kannon MA, **Lee CR**. *Effects of Acute Inflammation on Cardiovascular Cytochrome P450 and soluble epoxide hydrolase expression in mice in vivo*. 11<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 10, 2009.
7. **Lee CR**, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Tomer KB, Zeldin DC. *Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice*. 12<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010. "Travel Award" recipient.
8. **Theken KN**, Deng Y, Schuck RN, Kannon MA, Miller TM, Poloyac SM, **Lee CR**. *High-fat diet suppresses hepatic cytochrome P450 expression and metabolic activity in mice*. 12<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010. "Travel Award" recipient.
9. **Lee CR**, Pretorius M, Williams SM, Burch LH, Zeldin DC, Brown NJ. *Genetic variation in soluble epoxide hydrolase is associated with vascular responsiveness to bradykinin in humans*. 12<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010.
10. **Edin ML**, Wang Z, Bradbury JA, Graves JP, Lih FB, DeGraff LM, **Lee CR**, Zeldin DC. *Endothelial-specific overexpression of human CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart*. 12<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010.
11. **Theken KN**, Deng Y, Schuck RN, Kannon MA, Miller TM, Poloyac SM, **Lee CR**. *High-fat diet alters hepatic and renal cytochrome P450-mediated eicosanoid metabolism in mice*. 2010; [abstract PD-W-15]. 2010 Globalization of Pharmaceuticals Education Network Conference. Chapel Hill, NC, November 10, 2010.
12. **Lee CR**, Gordon LN, Pretorius M, Schuck RN, Burch LH, Zeldin DC, Williams S, **Brown NJ**. *Interactions between polymorphisms in eicosanoid metabolism genes and vasodilator responses in humans*. 14<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2012.
13. **Schuck RN**, Theken KN, Edin ML, Lih FB, Tomer KB, Caughey M, Hinderliter AL, Stouffer GA, Zeldin DC, **Lee CR**. *Association between cytochrome P450 derived eicosanoids and vascular function in humans with established coronary artery disease*. 14<sup>th</sup> Annual Winter

Eicosanoid Conference. Baltimore, MD, March 11, 2012. "Travel Award" recipient.

14. Kalish BT, Kieran MW, Le HD, Bielenberg DR, **Lee CR**, Edin ML, Greene ER, Vergilio JA, Hammock BD, Falck JR, Puder M, Zeldin DC, Panigrahy D. *Epoxyeicosatrienoic acids promote organ regeneration*. 14<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2012.
15. Oni-Orisan A, Deng Y, Schuck RN, Edin ML, Theken KN, Molnar K, DeGraff L, Zeldin DC, **Lee CR**. *Cyclooxygenase inhibition, CYP2J2 overexpression, and soluble epoxide hydrolase deletion similarly attenuate lipopolysaccharide-induced acute vascular inflammation*. 14<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 12, 2012. "Travel Award" recipient.
16. Cheng J, Edin ML, DeGraff LM, **Lee CR**, Falck JR, Zeldin DC. *In vitro cell proliferation, angiogenesis and oxidative stress are elevated in mice with endothelial-specific expression of human CYP4F2*. 14<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 12, 2012.
17. Puglisi J, **Lee CR**, Crane P. *Practice and outcomes in older adult coronary patients with low vitamin D*. 33<sup>rd</sup> Annual Gerontological Advanced Practice Nurses Association Conference. Orlando, FL. September, 2014.
18. Danford RC, Polasek M, Lee JA, Stouffer GA, **Lee CR**. *Retrospective analysis of clinical and CYP2C19 genetic predictors of anti-platelet therapy selection in patients undergoing percutaneous coronary intervention* [abstract #2-262]. 49<sup>th</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting. Orange County, CA. December 8, 2014.
19. Christensen ES, Oni-Orisan A, Lee JA, Stouffer GA, **Lee CR**. *Predictors of coronary artery disease progression and poor cardiovascular outcomes in patients referred for coronary angiography* [abstract #2-259]. 49<sup>th</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting. Orange County, CA. December 8, 2014.
20. Varunok N, Danford RC, Polasek M, Howell L, **Lee CR**, Stouffer GA. *Exploring the effects of genotype-guided P2Y12 inhibitor therapy on major adverse cardiovascular and clinically significant bleeding events in practice*. 161<sup>st</sup> North Carolina Medical Society Annual Meeting. Greensboro, NC. October 23, 2015.
21. Hamrick K, Polasek M, Stouffer GA, **Lee CR**. *Predictors of CYP2C19 genotype testing and anti-platelet therapy selection patients undergoing percutaneous coronary intervention* [abstract #5B-306]. 50<sup>th</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting. New Orleans, LA. December, 2015.
22. Li A, Dong O, Oni-Orisan A, Wiltshire T, **Lee CR**. *Projected impact of genotype-guided optimization of medication use: an opportunity for preemptive genotyping in cardiac catheterization laboratory patients* [abstract #240451]. 51<sup>st</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 5, 2016.
23. Wang N, Vendrov K, Simmons BP, **Lee CR**. *Evaluation of thromboxane A2 as a biomarker for predicting adverse cardiovascular outcomes in patients with stable coronary artery disease* [abstract #235223]. 51<sup>st</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 5, 2016.
24. Cervantes A, Sriramaju VB, Varunok N, Stouffer GA, **Lee CR**. *Utilization of a CYP2C19 genotype-guided antiplatelet treatment algorithm over time in patients undergoing percutaneous coronary intervention* [abstract #237805]. 51<sup>st</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 6, 2016.
25. Limdi NA, Holmes A, Skaar T, Cavallari L, Beitelshees AL, Dillon C, Duarte J, Empey PE, Gong Y, Hillegass WB, Johnson JA, **Lee CR**, Graves J, Garbett S, Zhou Z, Peterson JF. *Real world cost-effectiveness of CYP2C19 guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention* [abstract #PS3-14]. 39<sup>th</sup> Annual



Meeting of the Society for Medical Decision Making (SMDM). Pittsburgh, PA. October 24, 2017.

26. Khatri R, Bacheler R, Malinen M, Fallon JK, Sykes C, Smith PC, Kashuba ADM, Brouwer KLR, **Lee CR**. Pregnancy-related hormones increase nifedipine metabolism in sandwich-cultured human hepatocytes by inducing CYP3A expression. 48<sup>th</sup> Drug Metabolism Gordon Research Conference. Holderness, NH, July 9, 2018.
27. Robbins MJ, Rementer RJ, Williams A, Oni-Orisan A, **Lee CR**. Association between novel circulating biomarkers of cytochrome P450-derived eicosanoid metabolism and prognosis in patients with established atherosclerotic cardiovascular disease [abstract #556061]. 53<sup>rd</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting. Anaheim, CA. December 4, 2018.
28. Varma Y, **Lee CR**, Rossi J, Stouffer GA. Association of *CYP2C19\*17* allele and choice of P2Y12 inhibitor on cardiovascular outcomes following percutaneous coronary intervention [abstract #III-86]. Presented at the 2019 Society for Cardiovascular Angiography and Interventions Scientific Sessions. Las Vegas, NV, May 21, 2019.
29. Black RM, Williams AK, Stouffer GA, **Lee CR**. Projected impact of *CYP2C19* pharmacogenomic testing on optimizing medications in addition to antiplatelet therapy in a real-world setting [abstract #5-296]. 54<sup>th</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 9, 2019.

## **INVITED PLATFORM PRESENTATIONS**

### **Research**

1. *Evaluation of Phenotypic Probes of CYP2C9 Activity in a Genotyped Population*. American College of Clinical Pharmacy Annual Meeting, Cardiology Practice and Research Network, Los Angeles, CA, November 6, 2000.
2. *Metabolic Consequences of CYP2C9 Genetic Polymorphisms with Losartan*. American College of Clinical Pharmacy Annual Meeting, Cardiology Practice and Research Network, Tampa Bay, FL, October 23, 2001.
3. *CYP2C9 Genotype:Phenotype Relationships in Humans*. In-Vitro / In-Vivo Correlates of Drug Disposition Seminar, UNC School of Pharmacy, Chapel Hill, NC, February 21, 2002.
4. *Renal Dysfunction Is Common in Patients with Heart Failure and Preserved Systolic Function: Retrospective Analysis of the Digitalis Investigational Group (DIG) Trial*. American Heart Association Scientific Sessions 2003, Orlando, FL, November 10, 2003.
5. *Cytochrome P450 Derived Eicosanoids, Endothelial Function, and Cardiovascular Disease*. Division of Drug Delivery and Disposition Seminar, UNC School of Pharmacy, Chapel Hill, NC, March 2, 2004.
6. *Role of Cytochrome P450-Derived Eicosanoids in Endothelial Dysfunction and Cardiovascular Disease: Atherosclerosis Risk in Communities (ARIC) Ancillary Study*. Laboratory of Respiratory Biology Seminar, NIH/NIEHS, Research Triangle Park, NC, April 28, 2004.
7. *Twenty-four Hour Tolbutamide Plasma Concentrations as a Phenotypic Measure of CYP2C9 Activity in Humans*. American College of Clinical Pharmacy Annual Meeting, Dallas, TX, October 25, 2004.
8. *Cytochrome P450 Derived Eicosanoids, Endothelial Function, and Cardiovascular Disease*. Division of Pharmacotherapy and Experimental Therapeutics Seminar, UNC School of Pharmacy, Chapel Hill, NC, November 30, 2004.

9. *Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) and Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study*. Office of Clinical Research Seminar, NIH/NIEHS, Research Triangle Park, NC, March 8, 2005.
10. *EPHX2 Gene Polymorphism (K55R) and Cardiovascular Disease Risk: Results from the ARIC Study*. 7<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 22, 2005.
11. *Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) and Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study*. Laboratory of Respiratory Biology Seminar, NIH/NIEHS, Research Triangle Park, NC, April 20, 2005.
12. *Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) and Risk of Coronary Heart Disease: an Atherosclerosis Risk in Communities (ARIC) Study*. American Heart Association Scientific Sessions 2005, Dallas, TX, November 15, 2005. Winner, Elizabeth Barrett-Connor Research Award in Epidemiology for Young Investigators.
13. *Identification and Functional Characterization of Polymorphisms in Human Cyclooxygenase-1 (PTGS1)*. Laboratory of Respiratory Biology Seminar, NIH/NIEHS, Research Triangle Park, NC, February 8, 2006.
14. *Identification, Functional Characterization, and Potential Cardiovascular Disease Relevance of Polymorphisms in Human COX-1 (PTGS1)*. Division of Pharmacotherapy and Experimental Therapeutics Seminar, UNC School of Pharmacy, Chapel Hill, NC, February 21, 2006.
15. *Genetic Polymorphisms in Cyclooxygenase-1 (PTGS1): Functional Characterization and Association with Cardiovascular Disease Risk*. 8<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2006.
16. *Genetic Variation in COX-1 and COX-2 and Cardiovascular Disease Risk: The Atherosclerosis Risk in Communities (ARIC) Study*. Office of Clinical Research Seminar, NIH/NIEHS, Research Triangle Park, NC, April 4, 2006.
17. *Cytochrome P450 Derived Eicosanoids, Endothelial Function, and Cardiovascular Disease*. Doctoral Dissertation Defense, Division of Pharmacotherapy and Experimental Therapeutics, UNC School of Pharmacy, Chapel Hill, NC, July 11, 2006.
18. *Genetic Variation in the P450 Epoxygenase Pathway and Cardiovascular Disease Risk*. Cardiovascular Disease Epidemiology Program Seminar, Department of Epidemiology, UNC School of Public Health, Chapel Hill, NC, September 12, 2006.
19. *P450 Epoxygenases and Cardiovascular Disease: From Mouse to Man*. Drug Metabolizing Enzymes and Disease Pathogenesis Symposium, 2006 American Association of Pharmaceutical Scientists Annual Meeting, San Antonio, TX, November 1, 2006.
20. *Cyclooxygenase Polymorphisms: Functional Characterization and Implications for Cardiovascular Disease Risk*. Laboratory of Molecular Carcinogenesis Seminar, NIH/NIEHS, Research Triangle Park, NC, January 16, 2007.
21. *The G-765C Promoter Polymorphism in COX-2 (PTGS2), Aspirin Utilization and Cardiovascular Disease Risk: Atherosclerosis Risk in Communities (ARIC) Study*. Laboratory of Respiratory Biology Seminar, NIH/NIEHS, Research Triangle Park, NC, March 7, 2007.
22. *The G-765C Promoter Polymorphism in Cyclooxygenase-2 (PTGS2), Aspirin Utilization and Cardiovascular Disease Risk: The Atherosclerosis Risk in Communities (ARIC) Study*. 9<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2007.
23. *Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) is Associated with Vascular Responsiveness to Bradykinin in Humans*. 12<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010.
24. *Cytochrome P450 Epoxygenase Pathway and Cardiovascular Disease: Translation into Humans*. Grand Rounds in Clinical Pharmacology. Vanderbilt University Medical Center,

Nashville, TN, November 30, 2010.

25. *Cytochrome P450 Epoxygenase Pathway and Cardiovascular Disease: Translation into Humans*. Cardiovascular Disease Epidemiology Program Seminar, Department of Epidemiology, UNC School of Public Health, Chapel Hill, NC, March 29, 2011.
26. *Epoxyeicosanoids as a Potential Therapeutic for Inflammation and Atherosclerosis*. Therapeutic Targeting of Epoxyeicosanoids Symposium, Experimental Biology 2011, Washington, DC, April 12, 2011.
27. *The Role of Cytochrome P450-Derived Epoxyeicosatrienoic Acids (EETs) in Shock*. Eicosanoids and Shock Symposium, 14<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2012.
28. *Cytochrome P450 Derived Eicosanoids and Cardiometabolic Disease: Translation into Humans*. Department of Pharmaceutical Science, University of Alberta, Edmonton, Canada, April 27, 2012.
29. *Cytochrome P450 Derived Eicosanoids and Cardiovascular Disease: Translation into Humans*. Department of Pharmacology, New York Medical College, Valhalla, NY, June 13, 2012.
30. *Translational Characterization of Cytochrome P450-Mediated Eicosanoid Metabolism in Cardiometabolic Disease*. Lipid Oxidation and Chronic Disease Symposium, 2012 Southeast Lipid Research Conference, Pine Mountain, GA, September 28, 2012.
31. *Characterization of the Functional Relationship between Cytochrome P450-Mediated Eicosanoid Metabolism, Inflammation and Cardiometabolic Disease: A Translational Approach*. Bioactive Lipids Symposium, 2013 Drug Discovery and Therapy World Congress, Boston, MA, June 5, 2013.
32. *The Utility and Feasibility of Using CYP2C19 Genotype to Guide Dual Anti-Platelet Therapy Following PCI: Looking Back and Moving Forward*. Cardiovascular Grand Rounds. UNC Center for Heart and Vascular Care, Chapel Hill, NC, April 14, 2014.
33. *Cytochrome P450 Derived Epoxyeicosanoids as a Therapeutic Target in Non-Alcoholic Fatty Liver Disease*. Cytochrome P450 Derived Endogenous Bioactive Lipids Symposium, 21<sup>st</sup> International Symposium on Microsomes and Drug Oxidations (MDO2016). Davis, CA, October 3, 2016.
34. *Personalized Medicine Testing in Cardiology*. American Heart Association / American Stroke Association Mid-Atlantic Region Volunteer Leadership Summit, Chapel Hill, NC, February 2, 2017.
35. *Genomics in Medicine: CYP2C19 Genotype-Guided Selection of Antiplatelet Therapy in CAD Patients Undergoing PCI*. Genomics in Medicine Colloquium, Department of Genetics, UNC School of Medicine, Chapel Hill, NC, May 10, 2017.
36. *Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy after PCI*. Cardiovascular Grand Rounds, UNC Center for Heart and Vascular Care, Chapel Hill, NC, UNC School of Medicine, November 6, 2017.
37. *Genetic Variation in the CYP Epoxygenase Pathway, Endothelial Function, and Cardiovascular Disease Risk*. Genetics and Eicosanoids Symposium, 17<sup>th</sup> Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2018.
38. *Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy*. Graduate Program Seminar Series, Department of Pharmaceutical Sciences, University of Colorado-Denver Skaggs School of Pharmacy. Denver, CO. April 26, 2018.
39. *Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy after PCI*. Department of Pharmacotherapy and Translational Research

Seminar, University of Florida College of Pharmacy. Gainesville, FL. December 7, 2018.

40. *Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy after PCI*. Department of Pharmacy Practice and Translational Research Seminar, University of Houston College of Pharmacy. Houston, TX. April 18, 2019.
41. *Update on CYP2C19-Genotype Guided Antiplatelet Therapy after PCI: Clinical Implications of Emerging Evidence*. Cardiovascular Grand Rounds, UNC Center for Heart and Vascular Care, UNC School of Medicine, Chapel Hill, NC, October 14, 2019.
42. *CYP2C19-Genotype Guided Antiplatelet Therapy after PCI: Clinical Implications of Emerging Evidence*. Scientific Seminar Series, Marshfield Clinic Research Institute, Marshfield, WI (virtual), May 27, 2020.
43. *Observational Design Studies: Considerations for Pharmacogenomics and Biomarker Research*. Innovations and Transformations in Pharmaceutical Sciences-Virtual 2020 Conference. Chapel Hill, NC, July 22, 2020.

### **Continuing Education**

1. *New Medications on the Horizon*. New Directions in the Management of Heart Failure, Continuing Education, UNC School of Nursing, Chapel Hill, NC, October 23, 2002.
2. *Acute Coronary Syndromes: Treatment and Management*. Cardiac Medication Update, Continuing Education, UNC School of Nursing, Chapel Hill, NC, October 24, 2003.
3. *Biomarkers in Heart Failure* (break-out session). Heart Failure Management 2005: Established Therapy and New Frontiers, Amelia Island, FL, July 16, 2005.
4. *New Pharmacological Treatment Strategies for Patients with Cardiovascular Disease*. Cardiovascular Update: Disease Management & Prevention, Continuing Education, UNC School of Nursing, Chapel Hill, NC, September 22, 2005.
5. *Biomarkers and Genomics in Heart Failure* (break-out session). Heart Failure Management 2006: Established Therapy and New Frontiers, Amelia Island, FL, July 22, 2006.
6. *Biomarkers and Proteomics in Heart Failure* (break-out session). Heart Failure Management 2007: Established Therapy and New Frontiers, Amelia Island, FL, July 14, 2007.
7. *Personalized Medicine in CVD: Clinical Applications for Pharmacogenomics and Biomarkers* (break-out session). Heart Failure Management 2009: Established Therapy and New Frontiers, Amelia Island, FL, July 18, 2009.
8. *Cardiovascular Pharmacogenomics: A Review of Recent FDA Labeling Changes and Future Directions*. 21<sup>st</sup> Annual Rex Healthcare Update in Cardiology, Cary, NC, February 20, 2010.
9. *Pro-Con Debate on Prospective Study Designs: Convenience Cohorts versus Randomized Samples*. Conducting Pharmacogenomics Research: A Primer Symposium, 2010 American College of Clinical Pharmacy Spring Practice and Research Forum, Charlotte, NC, April 24, 2010.
10. *Personalized Medicine in CVD: Clinical Applications for Pharmacogenomics and Biomarkers* (break-out session). Heart Failure Management 2010: Established Therapy and New Frontiers, Amelia Island, FL, July 16, 2010.
11. *Update on Personalized Medicine in Cardiovascular Disease* (break-out session). Heart Failure Management 2011: Established Therapy and New Frontiers, Amelia Island, FL, July 22, 2011.
12. *Clopidogrel-CYP2C19 Black Box Warning: The Elephant in the Room*. ACCP Cardiology Practice and Research Network / AHA Clinical Pharmacology Committee Joint Symposium (*The "Me" Generation of Healthcare: Personalized Medicine in Cardiovascular Disease*), American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA, October 16, 2011.

13. *Application of Personalized Medicine Testing in Cardiology*. Personalized Medicine Conference for Pharmacists. Mission Health, Mountain Area Health Education Center, Asheville, NC, March 4, 2017.
14. *How to Interpret Patient Genotyping Data: Case Studies and Panel Discussion*. 11<sup>th</sup> Annual Chapel Hill Pharmaceutical Sciences Conference. Pharmacy in the Era of Precision Medicine: From Discovery to Implementation. Chapel Hill, NC, May 18, 2017.
15. *Implementing Pharmacogenetic Testing into Clinical Decision Making: Why, When and How?* Student National Pharmaceutical Association (SNPhA) Regional Conference. Chapel Hill, NC, February 24, 2018.
16. *Genetic Testing to Predict Medication Effects and Chronic Disease Risk in Cardiology: Is it Ready for Prime Time?* UF Precision Medicine Conference. University of Florida, Orlando, FL, March 9, 2018.

### **Educational**

1. *Immersion in Scientific Inquiry and Scholarship*. Inaugural Educational Renaissance Symposium: Toward a Curricular Transformation, UNC Eshelman School of Pharmacy, Chapel Hill, NC, December 18, 2012.
2. *Research and Scholarship in Pharmacy (RASP) Pathway*. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy. Houston, TX. April 18, 2019.

### **RESEARCH FUNDING – Active**

#### **Extramural**

##### **R03 HD092370-01-02**

Boggess, KA (PI)

Title: *Phase II Study of Nicotinamide (vitamin B3-amide) in Early-Onset Preeclampsia*  
 Sponsor: NIH/NICHD  
 Dates: 9/1/17 – 8/31/20 (2-years plus no cost extension)  
 Direct Costs: \$100,000  
 Effort: 2%  
 Role: Co-Investigator

##### **1 R01 HD098742-01**

Lee, CR (PI)

Title: *Mechanisms of Altered Hepatic Drug Metabolism and Transport in Pregnancy*  
 Sponsor: NIH/NICHD  
 Dates: 4/1/20 – 3/31/24  
 Direct Costs: \$1,060,523  
 Effort: 27.5%  
 Role: Principal Investigator

##### **1 R01 HL149752-01**

Cavallari, LH & Lee, CR (MPI)

Title: *Precision Antiplatelet Therapy after Percutaneous Coronary Intervention*  
 Sponsor: NIH/NHLBI  
 Dates: 7/15/20 – 7/14/25  
 Direct Costs: \$2,753,769 (total); \$809,319 (UNC)  
 Effort: 25%  
 Role: Multiple Principal Investigator (MPI), Consortium Lead Investigator



## **RESEARCH FUNDING – Completed**

### **Extramural**

- F32 ES012856 (Ruth L. Kirschstein Individual NRSA)** Lee, CR (PI)  
Title: *CYP2J2 Derived Eicosanoids and Endothelial Function*  
Sponsor: NIH/NIEHS  
Dates: 9/30/03 – 9/29/06  
Direct Costs: \$156,930  
Effort: 100%  
Role: Principal Investigator (fellow)  
Co-Sponsors: J. Herbert Patterson and Darryl C. Zeldin
- AHA 0765247U (Beginning Grant-in-Aid)** Lee, CR (PI)  
Title: *P450 Epoxygenase Pathway and Atherosclerotic Cardiovascular Disease*  
Sponsor: American Heart Association, Mid-Atlantic Affiliate  
Dates: 7/1/07 – 6/30/09  
Direct Costs: \$120,000  
Effort: 20%  
Role: Principal Investigator
- AFPE Pre-doctoral Fellowship Award** Theken, KN (PI)  
Title: *Role of Cytochrome P450-Mediated Eicosanoid Metabolism in Atherosclerotic Cardiovascular Disease*  
Sponsor: American Foundation for Pharmaceutical Education  
Dates: 9/1/08 – 8/31/11  
Direct Costs: \$18,000  
Effort: 0%  
Role: Major Advisor
- R01 GM088199-01-05** Lee, CR (PI)  
Title: *Cytochrome P450 Derived Eicosanoids and Inflammation*  
Sponsor: NIH/NIGMS  
Dates: 8/1/09 – 5/31/15 (5-years plus no cost extension)  
Direct Costs: \$1,053,568  
Effort: 40%  
Role: Principal Investigator
- T32 HL069768 (Ruth L. Kirschstein Institutional NRSA)** Maeda, N (PI)  
Title: *Pre-Doctoral Training Program in Integrative Vascular Biology*  
Sponsor: NIH/NHLBI  
Dates: 7/1/10 – 6/30/11  
Direct Costs: \$30,000  
Effort: 0%  
Role: Major Advisor (Robert N. Schuck)
- R01 GM088199-03-05S1** Lee, CR (PI)  
Title: *Cytochrome P450 Derived Eicosanoids and Inflammation (NIH Research Supplement to Promote Diversity in Health-Related Research)*  
Sponsor: NIH/NIGMS  
Dates: 6/1/11 – 5/31/14  
Direct Costs: \$47,400  
Effort: 0%  
Role: Principal Investigator

**AHA 11PRE7240059 (Pre-Doctoral Fellowship)** Schuck, RN (PI)

Title: *Translational Characterization of Arachidonic Acid Metabolism in Vascular Inflammation and Cardiovascular Disease*  
Sponsor: American Heart Association, Mid-Atlantic Affiliate  
Dates: 7/1/11 – 6/30/13  
Direct Costs: \$46,000  
Effort: 0%  
Role: Sponsor

**AFPE Pre-doctoral Fellowship Award** Oni-Orisan, A (PI)

Title: *The Role of Soluble Epoxide Hydrolase in Recovery Following Acute Myocardial Infarction: Translation from Mouse to Human*  
Sponsor: American Foundation for Pharmaceutical Education  
Dates: 9/1/12 – 8/31/13  
Direct Costs: \$6,500  
Effort: 0%  
Role: Major Advisor

**AHA 13PRE16470017 (Pre-Doctoral Fellowship)** Oni-Orisan, A (PI)

Title: *Soluble Epoxide Hydrolase and Cardioprotection: Translation from Mice to Humans*  
Sponsor: American Heart Association, Mid-Atlantic Affiliate  
Dates: 7/1/13 – 6/30/15  
Direct Costs: \$50,000  
Effort: 0%  
Role: Sponsor

**AFPE Gateway to Research Scholarship** Wells, MA (PI)

Title: *Translational Evaluation of Cytochrome P450-Derived Eicosanoid Metabolites as a Biomarker in Non-Alcoholic Steatohepatitis (NASH) Patients*  
Sponsor: American Foundation for Pharmaceutical Education  
Dates: 6/30/15 – 6/30/16  
Direct Costs: \$5,000  
Effort: 0%  
Role: Major Advisor

**AHA 16GRNT29300003 (Grant-in-Aid)** Lee, CR (PI)

Title: *Novel Biomarkers of Eicosanoid Metabolism in Coronary Artery Disease*  
Sponsor: American Heart Association, Mid-Atlantic Affiliate  
Dates: 7/1/16 – 6/30/19 (2-years plus no cost extension)  
Direct Costs: \$140,000  
Effort: 15%  
Role: Principal Investigator

**Project ID #18-2862 (Research Services Agreement)** Lee, CR (PI)

Title: *IGNITE Network CYP2C19-Clopidogrel Expansion Project*  
Sponsor: University of Florida  
Dates: 10/1/18 – 9/30/19  
Direct Costs: \$4,770  
Effort: 0%  
Role: Principal Investigator

**AHA 18POST33960403 (Post-Doctoral Fellowship)**

Khatri, R (PI)

Title: *Predicting Maternal Changes in Antihypertensive Drug Metabolism and Exposure during Pregnancy*  
Sponsor: American Heart Association  
Dates: 7/1/18 – 6/30/20 (early termination 11/1/2019)  
Direct Costs: \$114,368  
Effort: 0%  
Role: Sponsor

**Intramural****UNC Small Grant Program**

Lee, CR (PI)

Title: *Evaluation of a New Strategy for the Treatment of Vascular Inflammation*  
Sponsor: UNC University Research Council  
Dates: 5/1/07 – 4/30/09  
Direct Costs: \$5,000  
Effort: 0%  
Role: Principal Investigator

**UNC Investments in the Future**

Patterson, WC (PI)

Title: *Understanding Clinical Cardiovascular Disease and Health Disparities in North Carolina Using a Systems Biology Approach*  
Sponsor: UNC School of Medicine  
Dates: 7/1/07 – 6/30/08  
Direct Costs: \$243,333  
Effort: 5%  
Role: Co-Investigator

**UNC Junior Faculty Development Award**

Lee, CR (PI)

Title: *Dysfunctional Eicosanoid Metabolism and Cardiovascular Disease*  
Sponsor: UNC Office of the Provost  
Dates: 1/1/08 – 12/31/08  
Direct Costs: \$7,500  
Effort: 0%  
Role: Principal Investigator

**TraCS #2KR70909 (TraC\$2K Pilot Grant Program)**

Schuck, RN (PI)

Title: *Functional Characterization of a 5-Lipoxygenase Polymorphism in Patients with Atherosclerotic Cardiovascular Disease*  
Sponsor: The North Carolina Translational and Clinical Sciences Institute  
Dates: 9/1/09 – 8/31/10  
Direct Costs: \$2,000  
Effort: 0%  
Role: Major Advisor

**TraCS #10KR40907 (TraC\$10K Pilot Grant Program)**

Lee, CR (PI)

Title: *Eicosanoid Metabolism, Endothelial Function and Atherosclerotic Cardiovascular Disease*  
Sponsor: The North Carolina Translational and Clinical Sciences Institute  
Dates: 11/1/09 – 10/31/10  
Direct Costs: \$10,000  
Effort: 0%  
Role: Principal Investigator

**UNC Small Grant Program**

Lee, CR (PI)

Title: *Functional Characterization of an Interaction between the -765G>C Polymorphism in Cyclooxygenase-2 and Aspirin Use in Humans*  
Sponsor: UNC University Research Council  
Dates: 5/1/10 – 4/30/12  
Direct Costs: \$5,000  
Effort: 0%  
Role: Principal Investigator

**TraCS # 550KR61307 (TraC\$5K-\$50K Pilot Grant Program)**

Boggess, KA (PI)

Title: *A Dose Escalation Study of Nicotinamide Supplementation in Early Onset Preeclampsia*  
Sponsor: The North Carolina Translational and Clinical Sciences Institute  
Dates: 3/1/14 – 2/28/15  
Direct Costs: \$50,000  
Effort: 0%  
Role: Co-Investigator

**RX03512212 (Tier 1 Pilot Grant)**

Lee, CR (PI)

Title: *Solving the Mystery of Highly Variable Drug Disposition in Pregnant Women: Are Unique Hepatic Drug Metabolizing Enzymes Activated during Pregnancy?*  
Sponsor: The UNC Eshelman Institute for Innovation  
Dates: 10/1/15 – 3/31/17  
Direct Costs: \$49,855  
Effort: 15%  
Role: Lead Innovator

**RX03612214 (Tier 3 Pilot Grant)**

Wiltshire, T (PI)

Title: *Pharmacogenetic Implementation: The Actionable Genome*  
Sponsor: The UNC Eshelman Institute for Innovation  
Dates: 6/1/17 – 12/31/19  
Direct Costs: \$435,276  
Effort: 0%  
Role: Co-Investigator

**UNC Creativity Hub Pilot Award**

Gordon-Larsen, P (PI)

Title: *Heterogeneity in Obesity: Transdisciplinary Approaches for Precision Research and Treatment*  
Sponsor: UNC Office of the Vice Chancellor for Research  
Dates: 7/1/18 – 6/30/20  
Direct Costs: \$500,000  
Effort: 0%  
Role: Co-Investigator

## **TEACHING RECORD**

### **Professional**

#### ***Doctor of Pharmacy (Pharm.D.)***

##### **Course Director**

PHCY 624	Research and Scholarship in Pharmacy I	2017 - present
PHCY 725	Research and Scholarship in Pharmacy II	2017
PHCY 726	Research and Scholarship in Pharmacy III	2018

##### **Course Co-Director**

DPET 813	Advanced Cardiovascular Pharmacotherapy	2009 - 2015
PHCY 510	Foundations in Clinical Pharmacology	2016
PHCY 726	Research and Scholarship in Pharmacy III	2019 - present

##### **Instructor**

DPET 813	Advanced Cardiovascular Pharmacotherapy	2000 - 2016
PHCY 433	Drug Literature Analysis and Interpretation	2007 - 2009
PHCY 444	Pharmacotherapy 4: Cardiology / Nephrology	2009 - 2016
PHCY 510	Foundations in Clinical Pharmacology	2016 - 2019
PHCY 624	Research and Scholarship in Pharmacy I	2017 - present
PHCY 725	Research and Scholarship in Pharmacy II	2017 - present
PHCY 726	Research and Scholarship in Pharmacy III	2018 - present
PHCY 833	Advanced Cardiovascular Pharmacotherapy	2018

##### **Recitation Facilitator**

HAICC	Health Affairs Interdisciplinary Case Conference	2007 - 2009
PHCY 403	Pharmaceutical Care Lab III	2007 - 2012
PHCY 405	Pharmaceutical Care Lab V	2007 - 2010
PHCY 404	Pharmaceutical Care Lab IV	2008 - 2016
PHCY 402	Pharmaceutical Care Lab II	2009 - 2015
PHCY 601	Patient Care Lab	2016

##### **Reserve Facilitator**

PHCY 450	Pharmacotherapy 8: Problems	2008 - 2013
----------	-----------------------------	-------------

### **Graduate**

#### ***Ph.D. in Pharmaceutical Sciences***

##### **Course Director**

DPET 822	Advanced Clinical Pharmacy	2009 - 2016
DPET 833	Experimental Design Considerations in Clinical Research	2016 - present

##### **Course Co-Director**

DPET 833	Experimental Design Considerations in Clinical Research	2013 - 2015
----------	---	-------------

##### **Faculty Advisor**

PHRS	First Year Group, Pharmaceutical Science Graduate Program	2011
------	---	------

##### **Instructor**

MOPH 810	Drug Metabolism	2005 - 2015
DPET 832	Introduction to Applied Pharmacogenomics	2008 - 2016
DPET 833	Experimental Design Considerations in Clinical Research	2013 - present
DPMP 815	Drug Metabolism Module	2018 - present
DPET 837	Precision Therapeutics Through Genomics	2018 - present
DPOP 872	Proposal Writing	2018

##### **Small Group Discussion Facilitator**

DPET 822	Advanced Clinical Pharmacy	2009 - 2016
----------	----------------------------	-------------

## **Post-Graduate**

### ***UNC Clinical Research / Drug Development Fellowship program***

#### **Instructor**

DPET	Post-Doctoral 'Fellows Course'	2007 - 2008
DPET	T32 Fellows Forum	2014 - present

## **MENTORING RECORD**

### **Professional / Undergraduate**

#### ***Doctor of Pharmacy (Pharm.D.)***

##### **Research Advisor, PY4 students**

Chris Abernethy (co-advisor: Dr. Jo Ellen Rodgers)	2009 - 2010
Ryan Danford	2014 - 2015
Erin Christensen	2014 - 2015
Kasey Hamrick	2015 - 2016

##### **Research Advisor, Honors Program**

Michael Wells	( <i>AFPE Gateway to Research Scholar</i> )	2014 - 2016
Amy Li		2015 - 2017
Nan Wang		2015 - 2017
Alexandra Cervantes		2015 - 2018

##### **Research Advisor, Research and Scholarship in Pharmacy (RASP) pathway**

Melody Robbins		2016 - 2019
Jesse Martin	( <i>ASCPT Presidential Trainee</i> )	2016 - 2020
Spenser Smith		2017 - 2020
Rachel Black		2017 - 2020
Lindsay Ratner		2019 - present
Marshall Winget		2020 - present

#### ***Doctor of Medicine (M.D.)***

##### **Research Advisor, Carolina Medical Student Research Program (T35-DK007386)**

Nicholas Varunok (co-advisor: Dr. George A. Stouffer)	2015 - 2016
Melissa Klein (co-advisor: Dr. George A. Stouffer)	2017 - 2018
Chelsea Gustafson (co-advisor: Dr. George A. Stouffer)	2019 - 2020
Brian Wood (co-advisor: Dr. George A. Stouffer)	2020 - present

#### ***Undergraduate (B.S.)***

##### **Research Advisor**

Bobbie Nguyen (major: chemistry)	2013 - 2016
----------------------------------	-------------

## **Graduate**

### ***Ph.D. in Pharmaceutical Sciences***

#### **Major Advisor**

Katherine N. Theken, Pharm.D.	( <i>AFPE Predoctoral Fellow</i> )	2006 - 2011
Robert N. Schuck, Pharm.D.	( <i>AHA Predoctoral Fellow</i> )	2008 - 2013
Akinyemi Oni-Orisan, Pharm.D.	( <i>AFPE &amp; AHA Predoctoral Fellow</i> )	2010 - 2015

#### **Dissertation Advisory Committee**

Huali Wu, M.S.		2009 - 2010
Jasmine (Talameh) Luzum, Pharm.D.	( <i>AFPE Predoctoral Fellow</i> )	2009 - 2012
Christina Won, Pharm.D.		2012
Lawrence Ku, M.D. (Chair)		2015 - 2019
Olivia Dong, M.P.H. (Chair)	( <i>AHA Predoctoral Fellow</i> )	2016 - 2019



James Beaudoin, M.S.	(NIH NSRA F31 Predoctoral Fellow)	2017 - 2020
Jacqueline Gerhart, M.S. (Chair)		2019 - present
Jiawei Zhou, B.S. (Chair)		2020 - present
<b><i>Ph.D. in Epidemiology</i></b>		
<u>Dissertation Committee</u>		
Amanda Seyerle, M.S.		2015 - 2016
<b><i>External to UNC-Chapel Hill</i></b>		
<b><i>Ph.D. in Pharmaceutical Sciences (University of Alberta)</i></b>		
<u>Doctoral Final Oral Examination Committee (external member)</u>		
Ketul R. Chaudhary		2012
<b><i>M.S. in Clinical Research (Duke University)</i></b>		
<u>Research Advisor</u>		
Ewa Marczak, Ph.D.		2009 - 2011
<b><i>Ph.D. in Nursing (UNC-Greensboro)</i></b>		
<u>Dissertation Committee</u>		
Janis Puglisi, MSN, APRN, FNP-BC		2013
<b><u>Post-Graduate</u></b>		
<b><i>Post-Doctoral Research Fellows</i></b>		
<u>Major Advisor</u>		
Yangmei Deng, M.D., Ph.D.		2007 - 2011
Weibin Zha, B.S. Pharm., Ph.D.		2012 - 2013
Raju Khatri, M.S., Ph.D., DABT	(AHA Postdoctoral Fellow)	2017 - 2019
<b><i>UNC Clinical Research / Drug Development Fellowship program</i></b>		
<u>Major Advisor</u>		
Almasa Bass, Pharm.D. (co-advisor: Dr. J. Herbert Patterson)		2007 - 2008
Kyle Ellis, Pharm.D.		2008 - 2009
Bryant Tran, Pharm.D., M.S. (co-advisor: Dr. Jo Ellen Rodgers)		2009 - 2010
Savanna Steele, Pharm.D.		2010 - 2011
Brian Simmons, Pharm.D., M.S.C.R. (co-advisor: Dr. J. Herbert Patterson)		2011 - 2012
Robert Wittorf, Pharm.D.		2012 - 2013
John Andrew Lee, Pharm.D.		2013 - 2014
Melissa Polasek, Pharm.D.		2014 - 2015
Hitesh Patel, Pharm.D. (co-advisor: Dr. Robert Dupuis)		2017 - 2018
Alexis Williams, Pharm.D.		2018 - 2019
Megan Gower, Pharm.D.		2019 - present
<b><i>Pharmacy Residency</i></b>		
<u>Faculty Mentor, Residency Teaching Certificate Program</u>		
Brian Murray, Pharm.D.		2010 - 2011
Molly Howard, Pharm.D.		2013 - 2014
Frank Tillman, Pharm.D.		2019 - 2020
<b><i>Visiting Scholar</i></b>		
<u>Research Advisor</u>		
Vindhya B. Sriramoju, M.D. (co-advisor: Dr. George A. Stouffer)		2015 – 2017

## **Staff**

### ***Research Technician***

#### **Supervisor**

M. Alison Kannon, B.S.	2006 - 2011
Kimberly Vendrov, B.S.	2011 - 2015
Rebecca Rementer, M.S.	2016 - 2018
Natasha Kulick, B.A.	2018 - 2019

## **PROFESSIONAL SERVICE**

### **UNC-Chapel Hill**

#### ***UNC Eshelman School of Pharmacy***

#### **Standing Committees**

Pharm.D./Ph.D Program Committee	2007 - 2008
Admissions Committee	2008 - 2010
Graduate Education Committee	2008 - 2017
Assessment Committee	2010 - 2012
Student Portfolio Subcommittee (Chair)	2010 - 2011
Curricular Transformation Steering Committee	2012 - 2016
Scholarship Subcommittee (Chair)	2012
Pharmacy Innovation and Problem Solving Committee (Chair)	2013
Research/Scholarship Track Planning Team (Chair)	2016
Pharmacy Innovation and Problem Solving Planning Team	2016
Electives Planning Team	2016
Research and Scholarship in Pharmacy Oversight Committee (Chair)	2016 - present
Partnership in Patient Care 2.0 Research Working Committee	2018 - present
Budget Committee	2020 - present

#### **Ad Hoc Committees**

Information System Improvement Team	2008 - 2009
ACPE Accreditation Self-Assessment, Faculty/Staff subcommittee	2010 - 2011
Pharm.D./Ph.D Program Committee	2012
Virtual Patient Planning Team	2016 - 2017
Reviewer, ACPE Accreditation Self-Assessment, Educational Program for the Doctor of Pharmacy Degree subcommittee	2018 - 2019
COVID-19 Crisis Management, Research Enterprise Subcommittee	2020 - present
COVID-19 Clinical Research Review Committee	2020 - present

#### **Search Committees**

Assistant Director of Student Affairs, Office of Student Affairs	2012
Dean, UNC Eshelman School of Pharmacy	2019
Division Chair, Division of Pharmacotherapy and Experimental Therapeutics	2019 - 2020
Fixed-Term Assistant/Associate Professor (Biostatistics), Division of Pharmacotherapy and Experimental Therapeutics (Chair)	2019 - 2020
Program Manager (RASP / YIP), Office of Student and Curricular Affairs	2019 - 2020

#### **Miscellaneous**

Interviewer, Doctor of Pharmacy program applicants	2007 - 2019
Volunteer Pharmacist, IFC Shelter	2007 - 2008
Academic Advisor, Pharm.D. students	2014 - 2017

## ***Division of Pharmacotherapy and Experimental Therapeutics (DPET)***

### Administrative

Division Director of Graduate Admissions	2008 - 2016
Division Director of Graduate Studies	2016 - 2017
Vice Chair, Research and Graduate Education (Interim)	2019 - present

### Ad Hoc Committees

Graduate Student Clinical Experience subcommittee	2007
Written Qualifying Exam subcommittee	2008 - 2010
DPET Ph.D. Clinical-Track Stipend Supplement subcommittee	2012

### Miscellaneous

Interviewer, DPET Ph.D. program applicants (Recruitment Weekend)	2007 - present
Interviewer, DPET fellowship program applicants	2007 - present

## ***North Carolina Translational and Clinical Sciences Institute (NC TraCS)***

### Internal Grant Review Committee

Study Section Member, K-Scholars Program	2019 - present
--	----------------

## ***UNC McAllister Heart Institute (MHI)***

### Ad Hoc Committee

Co-Organizer, 2 <sup>nd</sup> Annual MHI Faculty Retreat	2019
--	------

## ***UNC Health Care and UNC School of Medicine***

### Ad Hoc Committee

Program for Precision Medicine and Health / Information Services Division	
Genetics and Genomics Governance Committee	2019 - present
Genomic Indicator Usage Working Group	2019 - present

## ***UNC Office of Research Development***

### Internal Grant Review Committee

American Diabetes Association Pathway to Stop Diabetes Award	2013 - 2014
--	-------------

## **National Institutes of Health**

### Institutional Review Board

Scientific Member (standing), NIH/NIEHS	2009 - 2014
Reviewer (ad hoc), NIH/NIEHS	2014 - 2017

### Scientific Reviewer (ad hoc)

Office of Clinical Research, NIH/NIEHS	2011 - 2013
--	-------------

### Study Section (ad hoc)

Special Emphasis Panel, 2010/05 ZES1 LWJ-V (01) 2	2010
Special Emphasis Panel, 2013/08 ZRG1 BDCN-A (40)	2013
Special Emphasis Panel, 2017/03 ZRG1 GGG D (90)	2017
Special Emphasis Panel, 2020/10 ZRG1 EMNR-S (55)	2020

### Research Network

Implementing GeNomics In PracTicE (IGNITE) Network, NIH/NHGRI	
Affiliate Member (UNC Lead Investigator)	2015 - present
Member, Pharmacogenomics Working Group	2015 - present

## **Professional Organizations**

### ***American College of Clinical Pharmacy (ACCP)***

Associate Member in Training	2000 - 2003
Full Member	2003 - present
Fellow	2011 - present
Cardiology Practice and Research Network (PRN)	2000 - present

#### **Service**

Abstract Reviewer, Annual & Spring Meetings	2003 - present
Member, Cardiology PRN Resident and Student Travel Award Committee	2008 - 2013
Reviewer, Resident and Fellow Travel Awards	2010 - 2011
Reviewer, Ambulatory Care Self-Assessment Program	2017
Member, Cardiology PRN Nominations Committee	2017 - 2019
Reviewer, Clinical Research Challenge	2019
Reviewer, Research Institute Futures Grant, Junior Investigator	2019
Member, Cardiology PRN Research and Scholarship Committee	2020 - present

### ***American Society of Clinical Pharmacology and Therapeutics (ASCPT)***

Associate Member	2002 - 2007
Full Member	2007 - present

#### **Service**

Abstract Reviewer, Annual Meeting	2016 - present
Member, Scientific Program Committee	2019 - present

### ***American Heart Association (AHA)***

Professional Member	2003 - present
Fellow	2015 - present
Council on Arteriosclerosis, Thrombosis and Vascular Biology	2003 - 2014
Council on Epidemiology and Prevention	2005 - 2009
Council on Genomic and Precision Medicine (GPM)	2009 - present
Council on Clinical Cardiology	2014 - present

#### **Service**

Member, Clinical Pharmacology Committee, Council on Clinical Cardiology	2013 - 2017
Member, Membership & Communications Committee, Council on GPM	2014 - 2018

### ***American Society for Pharmacology and Experimental Therapeutics (ASPET)***

Member	2006 - present
--------	----------------

#### **Service**

Co-Chair, <i>Therapeutic Targeting of Epoxyeicosanoids</i> symposium, Divisions of Cardiovascular/Molecular Pharmacology, Experimental Biology	2011
--	------

### ***Clinical Pharmacogenomics Implementation Consortium (CPIC)***

Scientific Member	2017 - present
Guideline Writing Committee Member, <i>CYP2C9-NSAIDs</i>	2018 - 2019
Subcommittee Member, <i>CYP2C9 Allele Function Assignment</i>	2019
Guideline Writing Committee Member, <i>CYP2C19-Clopidogrel</i>	2019 - present

### ***Heart Failure Society of America (HFSA)***

Member	2004 - 2011
--------	-------------

### ***The Eicosanoid Research Association***

#### **Service**

Poster Session Judge, International Winter Eicosanoid Conference	2007 - 2016
Organizer/Chair, <i>Advances in Eicosanoid Biology in Humans</i> symposium,	2011

International Winter Eicosanoid Conference	
Poster Session Co-Chair, International Winter Eicosanoid Conference	2012 - 2016
Scientific Advisor, International Winter Eicosanoid Conference	2015 - present
Co-Chair, <i>CYP450 Derived Endogenous Bioactive Lipids</i> symposium	2016
International Symposium on Microsomes and Drug Oxidations	
Co-Organizer/Chair, <i>Genetics and Eicosanoids</i> symposium,	2018
International Winter Eicosanoid Conference	

**Oak Ridge Associated Universities**

**Service**

Project Reviewer (Pennsylvania Department of Health)	2012
--	------

**Editorial Board**

Current Clinical Pharmacology	2005 - 2013
Frontiers in Physiology (Vascular Physiology)	2010 - present
Prostaglandins and Other Lipid Mediators	2011 - present
Frontiers in Genetics (Pharmacogenetics and Pharmacogenomics)	2012 - present

**Guest Editor**

Research Topic Host, Frontiers in Pharmacology	
<i>Double Edge Sword: Epoxyeicosatrienoic Acids in Health and Disease</i>	2014
Guest Editor, Prostaglandins and Other Lipid Mediators	
<i>Special Issue: Translational Significance of EETs and Other Fatty Acids in Obesity and Diabetes. Volume 125, Pages 1-118 (September 2016)</i>	2016

**Manuscript Referee**

Am J Pathol	Front Physiol	2006 - present
Am J Physiol Heart Circ Physiol	Gastroenterology	
Am J Physiol Endocrinol Metab	Genet Med	
Am J Physiol Regul Integr Comp Physiol	Hypertension	
Ann Pharmacother	JAMA	
Antioxid Redox Signal	J Am Heart Assoc	
Arterioscler Thromb Vasc Biol	J Am Soc Nephrol	
Atherosclerosis	J Invasive Cardiol	
Biol Rev	J Transl Med	
BMC Med Genet	J Pharmacol Exp Ther	
Br J Clin Pharmacol	Obesity	
Cancer Res	Personalized Medicine	
Cardiovasc Res	Pharmacogenet Genomics	
Circulation	Pharmacogenomics	
Circ Genom Precis Med	Pharmacogenomics J	
Circ Heart Fail	Pharmacol Res	
Clin Pharmacol Ther	Pharmacol Ther	
Clin Transl Sci	Pharmacotherapy	
Crit Care Med	Physiol Rev	
Curr Clin Pharmacol	Proc Natl Acad Sci U S A	
Drug Metab Dispos	Prostaglandins Other Lipid Mediat	
Environ Health Perspect	Sci Rep	
Expert Opin Drug Discov	Stroke	
Front Pharmacol		